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 The objectives of the dissertation research were to determine the role of denovo
synthesized fatty acids (DNFA) in the regulation of milk fat synthesis. Milk fat responses 
to increasing amounts of short- and medium-chain fatty acids (SMCFA), added in the 
proportion as synthesized denovo, were studied in lactating dairy cows. The results 
showed a significant linear increase in milk fat concentration with SMCFA 
supplementation. However, milk fat yield was similar for all treatments.  
A subsequent study was aimed at increasing the availability of SMCFA during 
trans-10, cis-12 CLA-induced milk fat depression (MFD) in lactating dairy cows to 
determine whether SMCFA can rescue part of CLA-induced MFD.  Post-ruminal 
infusion of butterfat (BF) was used as a source of SMCFA.  The BF treatment was 
compared to a mixture of fats containing only the long-chain FA (LCFA) with or without 
trans-10, cis-12 CLA infusion. Milk fat content and yield were significantly reduced with 
trans-10, cis-12 CLA. However, increased availability of SMCFA with BF infusion had 
no effects on milk fat yield and concentration. Trans-10, cis-12 CLA significantly 
 
 
reduced the mRNA expression of transcription factor SREBP-1c along with its 
downstream targets including ACC, FASN, LPL, SCD and AGPAT. The increased 
availability of SMCFA had no effect on either lipogenic gene or protein expression 
suggesting that nutritional manipulation was not sufficient to rescue trans-10, cis-12 
CLA-induced MFD.  
Finally, the effects of combination of a Rosiglitazone (ROSI), a PPAR-γ agonist, 
and trans-10, cis-12 CLA were examined on mammary and hepatic lipogenesis in 
lactating mice. Mammary lipogenesis was significantly reduced with trans-10, cis-12 
CLA, reducing the milk fat content and mRNA expression of lipogenic transcription 
factors SREBP1-c and PPAR- γ. Trans-10, cis-12 CLA significantly increased hepatic 
lipid accumulation, while the mRNA expression of SREBP1-c and PPAR- γ were not 
altered. On the contrary, ROSI had no effects on mammary lipogenesis. However, ROSI 
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Chapter 1: INTRODUCTION 
 
The composition of milk has been an important determinant of profitability for the 
dairy industry ever since the USDA Federal Milk Marketing System adopte a multiple 
component pricing system (MCP). This has changed the milk payment system for dairy 
producers to one based on the amounts of milk components produced rather than milk 
volume. Milk fat and milk protein are the most valuable milk components as compared 
with other solids (lactose and minerals) demonstrating powerful economic incentives for 
dairy producers to produce greater amounts of milk fat and milk protein (USDA-NASS, 
2009).  
Dietary manipulations in lactating cows offer a means for making rapid changes 
in the milk composition (Sutton, 1989). Milk fat responses to dietary manipulations have 
much greater impact on milk fat concentration and yield than on milk protein or other 
milk solids (lactose and minerals)(Sutton, 1989) . This signifies the importance of 
studying the metabolic regulation of milk fat synthesis. This would further help in 
developing practical guidelines for dairy farmers to better control the quality and quantity 
of milk fat according to market demands.   
Milk fat synthesis depends on two general sources of fatty acids (FA); i.e. denovo 
FA synthesis in mammary gland and transfer of preformed FA from blood triglycerides 
(TG).  Short-and medium-chain FA (SMCFA) including FA from C4-C14 and half of 
C16 are synthesized denovo while long-chain FA (LCFA) either originate from diet or 
are mobilized from adipose TG as preformed FA (Moore and Steele, 1968).   
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Milk fat content and yield can be reduced up to 50% (deVeth et al., 2003) by diets 
containing high levels of concentrates and polyunsaturated fatty acids (PUFA). The low 
milk fat syndrome commonly termed as milk fat depression (MFD) has been linked to 
unique FA intermediates produced during biohydrogenation (BH) of unsaturated FA in 
rumen (Bauman and Griinari, 2003). It has been shown that when intermediates in the 
BH process such as trans-10, cis-12 CLA accumulate, they are absorbed in the small 
intestine and subsequently interfere with milk fat synthesis in the mammary gland, 
resulting in MFD (Baumgard et al., 2000).  
Diet-induced MFD can also provide insights on regulatory aspects of milk fat 
synthesis. Milk fat depression is characterized by reduced mRNA abundance and enzyme 
activity of several mammary lipogenic enzymes in lactating dairy cows (Piperova et al., 
2000; Gervais et al., 2009), mice (Lin et al., 2004; Kadegowda et al, 2010) and rats 
(Ringesis et al., 2004). The coordinated downregulation of mammary lipogenic gene 
expression suggests transcriptional regulation of mammary lipogenesis (Harvatine and 
Bauman, 2006). Sterol regulatory element binding protein -1c (SREBP-1c) has been 
implicated as a major transcriptional regulator of mammary lipogenesis (Harvatine and 
Bauman, 2006). The mRNA abundance of SREBP-1c is downregulated by trans-10, cis-
12 CLA in mice (Kadegowda et al., 2010), lactating dairy cows (Harvatine and Bauman, 
2006) and in bovine mammary epithelial cells (Peterson et al., 2004). However, SREBP-
1c knockout mice failed to exhibit complete suppression of mammary lipogenesis, 
suggesting the role of other transcription regulators in FA synthesis (Liang et al., 2002). 
Recently, Bionaz and Loor (2008) proposed a pivotal role of PPAR- γ in controlling milk 
fat synthesis by serving as a regulator for SREBP activity. Further, a recent study 
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(Kadegowda et al., 2009) also showed marked upregulation of mammary lipogenic gene 
expression with Rosiglitazone, a PPAR-γ agonist, in bovine mammary epithelial cells. 
However, in their study trans-10, cis-12 CLA had no effects on PPAR-γ gene expression.  
The milk FA profile during trans-10, cis-12 CLA-induced MFD is characterized 
by reduced secretion of FA of all chain lengths. However, the effects are more 
pronounced for SMCFA than LCFA, suggesting inhibition of denovo FA synthesis 
(Bauman and Griinari, 2003). Short-and medium-chain FA are important for milk TG 
synthesis (Moore and Christie, 1979) and for maintaining fluidity of milk fat (Barbano 
and Sherbon, 1980). Since SMCFA accounts for approximately 50% of FA in ruminant’s 
milk (Moore and Christie, 1979) and 20-50% in rodent’s milk (Grigor MR, 1984) and  
are not present in typical feedstuffs, the only source for SMCFA is denovo FA synthesis 
in mammary gland. Recently, the importance of SMCFA during milk fat synthesis wa  
underscored when post-ruminal infusion of butterfat, used as a source of SMCFA, 
increased milk fat synthesis in lactating dairy cows (Kadegowda et al., 2008). This 
suggests that the mammary gland is responsive to SMCFA during normal milk fat 
synthesis. However, one could hypothesize that the responsiveness to SMCFA might be 
greater during MFD when the synthesis of these FA is inhibited.  
 Thus, the basic premise of this study is that denovo synthesized FA (DNFA) are 
limiting for milk fat synthesis and providing supplemental DNFA might prevent 
reduction in the milk fat yield and content during MFD. The central hypothesis of this 
proposal is that “the availability of denovo synthesized FA is the key limiting substrate 
for milk fat synthesis”.  
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Chapter 2: LITERATURE REVIEW  
Milk fat is the main energy component in milk and is also responsible for many of 
the physical, organoleptic and manufacturing properties of dairy products (Jensen, 2002). 
Milk fat is mainly composed of triglycerides (TG) with small amounts of phospholipids, 
cholesterol, diglycerides (DG), monoglycerides (MG) and free FA (FFA) (Jensen, 2002) 
and its synthesis is highly responsive to nutrition. Nutritional manipulation of milk fat 
provides a practical tool to alter its yield and composition (Bauman and Griinari, 2003). 
To appreciate fully the effect of nutrition on milk fat composition, it is important to be 
familiar with the metabolic pathways responsible for milk fat synthesis.  
Milk fat synthesis 
The basic mechanism of milk fat synthesis depends on two general sources of FA; 
i.e. denovo synthesis of FA in mammary gland and uptake of preformed FA from blood 
TG. The short-and medium-chain FA (C4-C14) and approximately 50% of C16 are 
synthesized within the mammary gland, whereas the remaining 50% of C16 and other 
long-chain FA (LCFA) are derived from the blood TG in circulating chylomicra and very 
low density lipoproteins (VLDL) (Bauman and Davis, 1974). 
Denovo fatty acid synthesis 
Denovo synthesis of FA is achieved by a sequence of reactions involving 
condensation of two-carbon (C-2) units derived initially from acetyl-CoA (Smith, 1994). 
Glucose, FA and glycerol are utilized as substrates for FA synthesis. However in 
ruminants the substrates for milk fat biosynthesis come from the volatile FA (V ); 
acetate and β hydroxy butyrate; produced during rumen fermentation. Denovo FA 
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synthesis is catalyzed by two key enzymes – Acetyl-CoA carboxylase (ACC) and Fatty 
acid synthase (FASN). Both enzymes are abundantly expressed in lipogenic tissues 
including liver, adipose tissue and lactating mammary gland (Kim, 1997).  
Acetyl-CoA carboxylase is a biotin containing enzyme catalyzing conversion of 
acetyl-CoA and biocarbonate to malonyl-CoA, a first rate limiting reaction in milk FA 
synthesis (AbuElheiga et al., 1997). ACC is responsible for regulating the amounts of FA 
in cell (Kim, 1997) with its two isozymes; ACC-α and ACC-β; involved in FA synthesis 
and oxidation, respectively (Wakil and Abu-Elheiga, 2009). While ACC-α is expressed 
more in lipogenic tissues and provides malonyl-CoA to the cells for FA synthesis 
(Lopezcasillas et al., 1991), ACC- β is expressed more in heart and skeletal muscles 
(AbuElheiga et al., 1997) and controls the mitochondrial FA oxidation. The role of ACC- 
β is supported by the fact that carnitine palmitoyl transferase (CPT-1), an essential 
component for mitochondrial oxidation, is extremely sensitive to inhibition by malonyl 
CoA generated by ACC- β (Kim, 1997). The activity of ACC can be regulated at various 
levels including short-term control with allosteric modulation by different metabolites 
(citrate, glutamate, free fatty acids, malonyl CoA, etc.) and reversibl  phosphorylation 
(AMP kinase, c-AMP dependent protein kinase, ACC kinase, etc.) at the serine residues 
and long-term regulation involving hormonal and nutritional control of gene regulation 
(Kim, 1997, Mao et al., 2003). 
Fatty acid synthase is a single multifunctional protein containing seven catalyti  
domains arranged in a series of connected globular domains (Wakil, 1989). These 
domains catalyze the elongation of acetyl-CoA by C-2 units derived from malonyl-CoA 
in a stepwise and sequential manner (Wakil, 1989). Six cycles of condensation result in 
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the formation of palmitic acid (C16), the predominant end product in eukaryotic cells 
(Bernard et al., 2008).  
Acyl moieties greater than C16 cannot be elongated by FASN and are susceptible 
to hydrolysis by thioesterase-I liberating palmitic acid (C16). A second thioesterase, 
Thioesterase II, in some species (rodents, rabbit, and humans) overrides thio terase I  
and results in early termination of FA synthesis, generating medium-chain FA (Barber et 
al., 1997). The presence of thioesterase II explains the varying proportions of medium-
chain FA in different species. On the contrary, ruminants lack thioesterase II. However, 
short-and medium-chain FA (SMCFA) are synthesized in ruminants due to intrinsic 
thioesterase activity of FASN (Bernard et al., 2008). Ruminant FASN exhibits an intrinsic 
transacylase capable of loading and releasing acyl chain from two to twelve carbons in 
length (Knudsen and Grunnet, 1982).  
Uptake of preformed FA by mammary gland 
  The incorporation of FA from plasma TG into milk fat involves their complete or 
partial hydrolysis by lipoprotein lipase (LPL). LPL is a member of the TG lipase family 
of proteins that exhibit significant TG esterase activity (Wang and Eckel, 2009). This 
enzyme is highly expressed in the lactating mammary gland and originates from 
mammary adipocytes unlike in other tissues such as skeletal muscle and adipose where it 
is synthesized in parenchymal cells and spreads along the vascular mesh (Wang and 
Eckel, 2009). The mammary activity of LPL markedly increases immediately prior to 
parturition and remains elevated throughout lactation, accompanied by concomitant 
downregulation in adipose tissue (Shirley et al., 1973). The site of its activity in the
7 
 
lactating mammary gland is the capillary lumen where it captures and hydrolyzes TG-rich 
lipoproteins to release FA (Neville and Picciano, 1997).  
 The FA released from TG and circulating non-esterified FA (NEFA) crosses the 
capillary endothelium and interstitial space to reach the mammary epithelial cel . Further, 
FA crosses the plasma membrane either by diffusion or a saturable transport sytem 
(Bernard et al., 2008). Several FA transporters including acyl-CoA binding proteins 
(ACBP)(Knudsen et al., 2000), clusters of differentiation (CD36)(Abumrad et al., 2000),  
fatty acid binding proteins (FABP) (Lehner and Kuksis, 1996) and ATP binding cassette 
(ABC) transporters (Klein et al., 1999) have been suggested as playing important roles in 
regulating FA transport and FA concentration in the cytoplasm of mammary epithelial 
cells.   
 Mammary epithelial cells contain an active st aroyl-CoA desaturase (SCD) 
enzyme. The mRNA abundance and enzyme activity of SCD increases at the onset of 
lactation, suggesting its importance during milk fat synthesis (Kinsella, 1970, Ward et al., 
1998).  SCD catalyzes the δ-9 desaturation of FA substrates by introducing a cis -9 
double bond mainly in C14 to C19 FA (Bernard et al., 2008), converting saturated FA to 
monounsaturated FA (Grummer, 1991). About 40% of stearic acid taken up by the gland 
is desaturated, contributing to more than 50% of oleic acid secreted in milk fat (Bickerst 
et al., 1974, Chilliard et al., 2000). In bovine mammary gland, SCD is also responsible for 





Triglyceride (TG) synthesis 
The synthesis of TG involves addition of FA to the sn-1, sn-2, and sn-3 positions 
of the glycerol backbone (Bernard et al., 2008). The major pathway for TG biosynthesis 
in the mammary gland is the sn-glycerol 3-phosphate pathway involving the formation of 
phosphatidic acid using two acyl moieties (Dils, 1983). The first step in TG biosyntheis 
is catalyzed by glycerol-3-phosphate acyl transferase (GPAT) where FA are esterified 
with glycerol-3-phosphate at the sn-1 position. The second step is committed by acyl
glycerol phosphate acyl transferase (AGPAT) which catalyzes FA esterification at the sn-
2 position. Diglycerides (DG) is synthesized by hydrolyzing the phosphate group at sn-3 
position with enzyme phosphatidate phosphatase (Moore and Christie, 1979).The final 
step of TG synthesis is catalyzed by di-acyl glycerol acyl transferase (DGAT). DGAT is 
the only protein that is specific to TG synthesis and therefore might play an important 
regulatory role (Mayorek et al., 1989).  
The position of FA along the glycerol backbone affects the nutritional and 
functional attributes of milk fat (Bernard et al., 2008). Fatty acids are not distributed 
randomly on sn-1, sn-2, and sn-3 positions. In ruminants, short chain FA, SCFA (C4-C6) 
are almost exclusively (95%) esterified to the sn-3 position in milk fat. All of the C4, 
93% of C6 and 63% of the C8 have been shown to be esterified to the sn-3 position 
(Jensen, 2002). The distributions of other FA in the TG appear to vary depending on the 
molecular weight of the TG (Parodi, 1982). The C10, C12 and C14 FA are predominantly 
found in the sn-2 position. Palmitate (C16:0) is almost equally distributed between the sn-
1 and sn-2 positions. Oleate (C18:1) is preferentially distributed in the sn-3 position in 
high molecular weight TG and at sn-1, in the low molecular weight TG whereas stearate 
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(C18:0) selectively esterifies at the sn-1 position (Parodi, 1982). Unsaturated FA are 
preferentially esterified at the sn-3 position in higher molecular weight TG. Though the 
exact mechanisms involved in the positioning of the FA in milk fat TG in ruminants is 
not clearly understood, specific mammary acyltransferases may be involved (Paro i, 
1982).  
Transcriptional regulation of lipid synthesis 
 Based on previous studies it has been suggested that genes involved in milk fat 
synthesis might share a common regulatory mechanism via transcription facrs (Clarke, 
2001). The major transcription factors involved in lipid metabolism are sterol regulatory 
element binding protein-1 and Peroxisome proliferator activated receptors (PPARs) 
(Bernard et al., 2008). 
Sterol regulatory element binding protein (SREBP)   
Sterol regulatory element binding protein is the major transcriptional factor 
associated with regulation of cholesterol and lipid metabolism (Brown and Goldstein, 
1997). SREBP are members of the basic-helix-loop-helix-leucine zipper family of  
transcription factors synthesized as a 1150 amino acid precursor that is attached to the 
nuclear envelope and membrane of the endoplasmic reticulum (Wang et al., 1994). These 
are structurally composed of 3 segments with two membrane spanning regions. The –
NH2 terminal transcription factor domain consists of ~480 amino acids, –COOH 
regulatory domain consists of ~590 amino acids and one hydrophobic region of ~80 




Following translation, SREBP precursors bind to the SREBP cleavage activating 
protein (SCAP) (Sakai et al., 1998). SCAP interacts with INSIG-1 (Insulin induced gene) 
proteins, which retain the SCAP/SREBP complex in the ER compartment (Yang et al., 
2002). The SREBP cleavage can be controlled by cellular sterol content due to the 
presence of a sterol sensing domain on SCAP (Nohturfft et al., 1998). The SREBP-SCAP 
complex is retained on the ER in the presence of high sterol concentrations, while during 
low sterol concentrations ,the SREBP-SCAP complex is detached from INSIG proteins 
(Figure 2.1), allowing the SCAP to escort SREBP to the golgi apparatus (Sakai et al., 
1998). Upon activation, the SREBP precursor undergoes a sequential two-step cleavage 
process by two proteases, site1 protease (S1P) and site 2 protease (S2P) to release a 68-
kDa mature SREBP (Sakai et al., 1998, Wang et al., 1994), then the mature protein is 
translocated to the nucleus where it binds the target genes on sterol response elements 
(SRE) as a homodimer. 
 
Figure 2.1. The SREBP pathway 
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isotypes are generally co-expressed in all cell types but their relatve levels of expression 
vary from one cell to another (Jain et al., 1998). PPAR heterodimerize with retinoid X 
receptor (RXR) and regulate the expression of genes containing the peroxisome 
proliferative response element (PPRE) (Berger and Moller, 2002). 
Peroxisome proliferator activated receptors-γ i  an important member of the 
nuclear receptor super family of transcription factors that can be activated by lipophilic 
ligands. It regulates adipocyte differentiation and has been implicated as a key protein for 
thermogenesis and lipid metabolism in adipose tissue (Jain et al., 1998). It also 
suppresses macrophage cytokine production reducing inflammatory responses (Jiang et 
al., 1998). While PPAR-γ is known to promote adipogenesis in adipose, its role in the 
mammary gland is still uncertain (Wan et al., 2007). Targeted deletion of PPAR-γ gene in 
mice resulted in production of milk containing elevated levels of inflammatory lipids 
causing alopecia, inflammation, and growth retardation in mouse pups following milk 
consumption (Want et al., 2007). This suggests a pivotal role of PPAR-γ in maintaining 
milk quality and suppressing the production of inflammatory lipids.  Bionaz and Loor 
(2008) showed increased expression of PPAR-γ with the onset of lactation and proposed 
that the role of PPAR-γ in lactating mammary gland might be pivotal by controlling the 
activities of INSIG-1 which further controls the formation of active SREBP-1. 
Simultaneous increases in genes related to FA uptake, transport synthesis, and 
desaturation were also observed, suggesting that the part of LCFA effects may have been 
mediated through PPAR-γ (Bionaz and Loor, 2008). Recently, Kadegowda et al., (2009) 
showed that the activation of PPAR-γ via its agonist Rosiglitazone in bovine mammary 
epithelial cells (MAC-T) upregulates mammary lipogenic mRNA expression including 
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gene expression for denovo FA synthesis. PPAR-γ also activates a subset of transcription 
factors namely SREBP-1and 2.   
 
Nutritional regulation of milk fat synthesis 
 Various factors influence milk fat synthesis in dairy cattle including genetics, 
breed, stage of lactation, environment, parity and nutrition. This section deals only with 
nutritional regulation of milk fat synthesis.  The nutritional control of milk fat syn hesis 
has been extensively studied to improve the manufacturing properties of milk and to 
enhance the beneficial fatty acids in milk fat (Jenkins and McGuire, 2006). Various 
factors like amount and type of roughage, forage particle size, roughage to concentrate 
ratio, amount and type of lipids, intake and meal frequency are among the most important 
dietary factors affecting milk fat synthesis, and subsequently, FA composition (Sutton, 
1989).    
  Milk FA composition is markedly affected by the FA composition of the diet in 
most species (Neville and Picciano, 1997). However, in ruminants, the FA profile of the 
diet is markedly altered by ruminal microbial metabolism; thus, milk FA composition 
does not reflect the dietary FA profile. However diet can still have major effects on milk 
fat synthesis even in ruminants as it can markedly affect the microbial populati n and 






When dietary constituents enter the rumen, a wide range of chemical 
transformations occur as a result of microbial fermentation (Harfoot, 1978). Dietary 
lipids are hydrolyzed to free fatty acids by microbial lipases and unsaturated f ee FA are 
further biohydrogenated into saturated FA as a detoxification mechanism to protect
rumen microbes (Henderso, C. 1973). This results in marked differences between the FA 
profile of the diet and FA profile of the lipids leaving the rumen (Harfoot and 
Hazlewood, 1988).  
 The earliest evidence of ruminal biohydrogenation (BH) was observed when 
linolenic acid (C18:3) content of linseed oil was significantly reduced in ruminal fluid of 
sheep accompanied by a concomitant increase in the content of linoleic acid (C18:2) 
(Reiser, 1951, Shorland et al., 1955). Several studies have shown that the first step in BH 
of both linolenic and linoleic acid is isomerization of the cis-12 bond, forming several 
monoene and diene derivatives containing trans-11 bonds (Figure 2.2) (Harfoot and 
Hazlewood, 1988).  Recently the presence of multiple CLA intermediates (cis-10, cis-12, 
cis-9, cis-11 and trans-8, trans-10) during linolenic and linoleic acid BH have indicated 
that the pathways are much more complex than initially reported and include several 
other intermediates before eventual conversion to stearic acid (Jenkins et al., 2008, Lee 
and Jenkins, 2011). The conversion of oleic acid to stearic acid involves formation of 
various trans-C18:1 intermediates with double bonds at 6,7,9-16 positions (Mosley et al., 
2002).  The rumen BH also occurs on C20 and C22 FA. The disappearance of C20:5 
(eicosapentanoic acid, EPA) and C22:6 (docosahexaenoic acid, DHA) is extensive 
however these FA do not become fully saturated. Instead numerous intermediate 
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compounds are produced (Chilliard et al., 2000). Due to an unknown mechanism the 
addition of DHA and/or EPA increases the ruminal production of trans C18:1 FA. 
Possibly, DHA and EPA are either converted to trans C18:1 isomers or increases the 
formation of trans 18:1 isomers from C18 unsaturated FA biohydrogenation. Recent 
study, using uniformly 13-C-labeled DHA, has suggested that supplementing DHA alters 
the rumen BH pathways resulting in increased trans FA isomers that are absorbed and 
transferred into milk (Klein and Jenkins, 2011). 
 
Figure 2.2. Biohydrogenation pathways of unsaturated FA (Harfoot and Hazlewood, 
1988) 
 The extent of BH is dependent on the type of diet (Chilliard et al., 2000). High 
concentrates can reduce the pH in rumen and shift the profile of the microbial population 
and volatile FA (VFA) pattern. It further limits lipolysis, and subsequently BH, which 
occurs only on free FA (Chilliard et al., 2000). In the case of a marine oil diet, the rumen 
pH and VFA pattern are not affected. However, the FA in marine oil alter microbial 
processes by directly affecting critical steps in BH processes, further altering the end 
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products of ruminal BH. As a result of diet-induced alternations in rumen fermentation, 
unique FA intermediates including trans-10 C18:1 and CLA isomers accumulate which 
are potent inhibitors of milk fat synthesis (Klein and Jenkins, 2011). In the following 
section the role of CLA isomers on mammary and hepatic lipid metabolism will be 
discussed.   
Conjugated linoleic acid (CLA) 
Conjugated linoleic acid refers to a group of dienoic derivatives of linoleic acid 
with conjugated double bonds arranged in different combinations of ci and trans 
configuration (Pariza et al., 2001). Currently, 16 naturally occurring CLA isomers have 
been identified with different positional (7/9, 8/10, 9/11, 10/12, 11/13) and geometric 
(cis/cis, trans/trans, cis/trans, trans/cis) combinations (Eulitz et al., 1999; Sehat et al., 
1999).   
The sources of CLA include those naturally present in dairy products and meat 
from ruminant animals or those contained in industrially hydrogenated vegetable oils 
such as margarines and other synthetic products (Park and Pariza, 2007).  The 
predominant CLA isomer originating from the ruminant products is cis-9, trans-11 CLA 
(>80%), with small amounts of trans-10, cis-12 CLA and other isomers (Parodi, 1977). 
The industrially synthesized CLA and other commercial products intended for human 
consumption typically consist of equal amounts of cis-9, trans-11 CLA and trans-10, cis-
12 CLA and other isomers (Chin et al., 1992). Of all of the CLA isomers, cis-9, trans-11 
CLA and trans-10, cis-12 CLA have been the most widely studied due to their 
biologically active properties (Pariza et al., 2001). 
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Physiological effects of CLA 
Much of the current interest in dietary CLA is due to their anti-carcinogenic (Chin 
et al., 1992), anti-atherogenic (Lee et al., 1994), and immunity enhancing properties 
(Miller et al., 1994), and effects on body composition (Park et al., 1997).  Each CLA 
isomer has unique bioactive properties, and hence, the biological effect from a mixture of 
dietary CLA isomers, as is the case in most of the studies, would be the combined effect 
of their distinct isomers (Pariza et al., 2001).  For example, cis-9, trans-11 CLA and 
trans-10, cis-12 CLA have additive effects on cancer (Ip et al., 2002), and immune cell 
functions (Belury, 2002) but are antagonistic with respect to insulin sensitivity (Park and 
Pariza, 2007). While cis-9, trans-11 CLA improves insulin sensitivity, trans-10, cis-12 
CLA causes insulin resistance (Park and Pariza, 2007).  Also, trans-10, cis-12 CLA is 
solely responsible for changes in body composition and reducing adipose mass (Park et 
al., 1999b). 
Body Weight and Lean Mass 
  CLA reduces body weight and body fat mass and increases lean mass in 
different species (Park et al., 1997).  However, the response appears to vary depending on 
species, physiological stage, and fat depot (Larsen et al., 2003, Park et al., 1997).  Table 
2.1 provides a summary of studies reviewed across species with respect to body weight 
and adiposity where the number of experiments showing significant (P < 0.05) increases, 
decreases, or no change, and the mean response to dietary trans-10, cis-12 CLA within 
those categories are reported.  The range of trans-10, cis-12 CLA addition in these 
studies varied between 0.1 to 1% of the diet.  
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Trans-10, cis-12 CLA reduces body fat to a maximum extent in mice (60 to 80%) (Ide, 
2005; Andreoli et al., 2009). However, modest and inconsistent effects are seen in rats 
(Purushotham et al., 2007; Gudbrandsen et al., 2009) hamsters (9 to 58%) (Zabala et al., 
2006; Miranda et al., 2009) and pigs (6 to 25%) (Whigham et al., 2007). Similarly, 
variable responsiveness to CLA was observed for epididymal, perirenal and subcutaneous 
body fat depots (Zabala et al., 2006). Inconsistent responses to trans-10, cis-12 CLA have 
been reported in clinical trials with humans (Bhattacharya et al., 2006). Some have shown 
significant effects on body composition (Blankson et al., 2000, Thom et al., 2001) while 
others have not (Zambell et al., 2000; Petridou et al., 2003). The differences in the 
responses are attributed to differences in the dose levels, age, and rate of adipose tissue 
TG turnover (Malpuech-Brugere et al., 2004; Bhattacharya et al., 2006; Park and Pariza, 
2007). The response to CLA isomers also depends on the physiological state of the 
animal, which is probably due to differences in the preferential uptake of CLA by 
different tissues. For example, trans-10, cis-12 CLA is preferentially taken up by the 
mammary tissue during lactation leading to a substantial (~45%) decreas in milk lipid 
synthesis (Kadegowda et al., 2010).  
Effects of CLA on hepatic lipid metabolism  
   Liver plays an important role in energy homeostasis as it converts excessive 
dietary glucose into FA, which are exported as TG.  Liver is an important target issue for 
CLA effects irrespective of the physiological condition.  Of the different CLA isomers, 
trans-10, cis-12 CLA causes increased lipid accumulation leading to hepatic steatosis 
(Clement et al., 2002; Degrace et al., 2003; Rasooly et al., 2007; Cooper et al., 2008). 
However, the intensity of lipid accumulation varies depending on the CLA concentration 
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in the diet, duration of feeding, physiological condition, and animal species (Table 2.1). 
The factors leading to hepatic lipid accumulation are multi-factorial involving increased 
FA influx, increased FA synthesis and altered FA oxidation and TG secretion insufficient 
to prevent lipid accumulation (Jourdan et al., 2009). These mechanisms are probably not 
mutually exclusive, and could act in a coordinated manner to hasten the development and 
progression of fatty liver (Gentile and Pagliassotti, 2008).  
Hepatic FA Synthesis   
Under normal conditions denovo lipogenesis contributes minimally to the lipid 
pool in the liver (Diraison and Beylot, 1998).  However, the lipid synthesis increases to as 
much as 26% during steatotic conditions (Figure 2.3) (Donnelly et al., 2005). The increase 
in hepatic lipid content due to CLA, specifically trans-10, cis-12 CLA, is commonly 
associated with increased hepatic lipogenesis (Clement et al., 2002).  In mice, CLA has 
been repeatedly shown to increase the expression of SREBP-1c, a key transcriptional 
regulator in hepatic lipogenesis and its down-stream genes acetyl-CoA carboxylase (ACC), 
fatty acid synthase (FASN), and stearoyl-CoA desaturase-1 (SCD1) (Clement et al., 2002; 
Takahashi et al., 2003; Liu et al., 2007) (Table 2.2).  However, in rats and hamsters, the 
responses are equivocal.  The increase in SREBP-1c expression in mice is attributed to 
hyperinsulinimia (Clement et al., 2002). The decreased expression of lipogenic (ACC1, 
ACC2, FASN and SCD1) genes in the absence of insulin in mice fed trans-10, cis-12 CLA 
further supports this argument (Jourdan et al., 2009). In addition to SREBP-1c, insulin 
induces the expression of PPAR-γ (Boelsterli and Bedoucha, 2002) which is in low 
abundance under normal conditions (Tontonoz et al., 1994). PPAR-γ expression is 
increased in steatotic liver (Clement et al., 2002, Zhang et al., 2006) while its ablation 
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ameliorates the condition in mice (Gavrilova et al., 2003). Insulin resistance in response to 
trans-10, cis-12 CLA could up-regulate genes of the glucogenic pathway (e.g., PEPCK, 
G6P) leading to hyperglycemia (Denechaud et al., 2007).  In turn, elevated blood glucose 
concentrations could up-regulate hepatic lipogenesis through carbohydrate response 
element binding protein (ChREBP), a transcriptional regulator modulated by glucose. The 
targeted deletion of ChREBP in the liver improves the steatotic conditions in ob/ob mice 
(Denechaud et al., 2007). However, the role of ChREBP in CLA-induced hepatic steatosis 
is not known. Although hyperinsulinemia triggers the hepatic lipogenesis, CLA-induced 
hepatic steatosis in the absence of insulin suggests the involvement of other regulato y 
mechanisms affecting hepatic lipid accumulation (Jourdan et al., 2009).  
Hepatic FA uptake and TG secretion  
In experiments using mouse as experimental model, dietary trans-10, cis-12 CLA 
was associated with up-regulation of genes associated with FA uptake and TG secretion 
(FAT/CD36; Table 2.2, Figure 2.3). During hepatic steatosis 59% of hepatic TG is 
derived from free FA released from the adipose tissue and 15% is derived from dietary
fat (Donnelly et al., 2005).  FA transporters, (FATP5, FAT/CD36, FABP-1, FABP-4, and 
FABP-5) regulate the FA uptake by hepatocytes. While the over-expression of these 
proteins promotes steatosis, functional deletion ameliorates the condition (Doege et al., 
2006; Zhou et al., 2008; Musso et al., 2009). As CLA are natural ligands and activators of 
PPAR-γ (Belury et al., 2002), the up-regulation of FAT/CD36 by trans-10, cis-12 CLA 
(Degrace et al., 2006, Jourdan et al., 2009, Rasooly et al., 2007) could be through PPAR-γ 
leading to increased hepatic FA uptake. In addition to FAT/CD36, modest increases have 
been observed in the expression of FABP-1 (1.39 fold) and FABP-2 (1.7 fold) in liver of 
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lactating mice fed trans-10, cis-12 CLA (Kadegowda, A.K.G., Erdman, R.A., and Loor, 
J.J. Unpublished results).  
Besides enhanced FA uptake and lipogenesis, alteration in very low density 
lipoprotein (VLDL) secretion rates could also result in hepatic fat accumulation 
(Nagayoshi et al., 1995).  The VLDL production and secretion are increased in response 
to elevated lipid concentrations.  However, impaired or insufficient fat export via VLDL 
predisposes animals to hepatic steatosis (Charlton et al., 2002).  Trans-10, cis-12 CLA 
reduced TG secretion, leading to greater lipid accumulation in HepG2 cells due to 
reduced apolipoprotein B synthesis (Lin et al., 2001).  Conversely, lipoprotein clearance 
was not affected in mice fed CLA (Degrace et al., 2003; Degrace et al., 2006). The TG 
export was increased with faster rates of VLDL secretion however it was insufficient to 
eliminate increased FA flux entering the liver, leading to hepatic steatosis (Degrace et al., 
2003).  
Hepatic FA Oxidation  
Hepatic FA oxidation encompasses β-oxidation in mitochondria and peroxisomes 
and ω-oxidation in the microsomes (Reddy and Hashimoto, 2001). The FA from C8 to 
C20 are catabolized through the mitochondrial β-oxidation pathway while FA >C20 are 
initially catabolized in the peroxisomes to shorter FA which are then shuttled to 
mitochondria for further oxidation (Rasooly et al., 2007). Previous studies have reported 
variable responses in hepatic FA oxidation with trans-10, cis-12 CLA. Most of the 
studies have shown increased FA oxidation (Takahashi et al., 2003; Degrace et al., 2004; 
Javadi et al., 2004; Ide, 2005; Macarulla et al., 2005) while some have reported reduce 
(Rasooly et al., 2007) or unaltered FA oxidation (Park et al., 1997) with CLA. 
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Carnitine palmitoyltransferase-1 (CPT1) is the rate limiting enzyme for the 
mitochondrial β-oxidation pathway as it regulates the transport of fatty acyl CoA into 
mitochondria. When measured in mice, CPT1 gene expression was consistently increased 
by CLA (Table 2.2) which might be mediated through transcriptional regulator PPAR-α, 
as it regulates the key enzymes (e.g., CPT1, CPT2, ACO) involved in hepatic FA 
oxidation (Moya-Camarena et al., 1999).  
Despite increased FA oxidation, hepatic steatosis was consistently observed in 
mice fed CLA (Table 2.1, 2.2). Since studies showing increased FA oxidation were also 
associated with increased hepatic lipogenesis, it is possible that that the rates of hepatic 
lipogenesis far exceed the rates of FA oxidation, resulting in increased lipid 
accumulation. Along with increased lipogenesis, the level of malonyl CoA, a product of 
ACC, was also increased which allosterically inhibits CPT1 enzyme activity (Degrace et 
al., 2004). Thus despite higher expression of FA oxidation genes, it is possible that FA 
oxidation might be depressed in-vivo leading to steatosis.  
Some studies have shown CLA-induced down-regulation of genes related to 
mitochondrial β-oxidation (CPT1),  and ω oxidation (cyt P450 and FMO3) (Rasooly et 
al., 2007) .The expression of CPT1, ACOX1, and FMO3 was decreased without any 
changes in hepatic lipogenic genes of lactating mice fed trans-10, cis-12 CLA 
(Kadegowda, A.K.G., Erdman, R.A., and Loor, J.J. Unpublished results).  The variable 
responses among different studies can be attributed to the level and type of fat used in the 





Effect of CLA on hepatic fatty acid composition. 
 Trans-10, cis-12 CLA-induced hepatic steatosis is characterized by changes in 
hepatic FA composition (Figure 2.3) (Belury and KempaSteczko, 1997; Sebedio et al., 
2001; Chardigny et al., 2003; Kelley et al., 2004; Kelley et al., 2006; Kadegowda et al., 
2010; Martins et al., 2011) similar to those induced during non-alcoholic fatty liver 
disease (NAFLD) (Puri et al., 2007).  The hepatic FA composition in steatotic liver 
determines the extent of susceptibility of liver injury (Wang et al., 2006). The steatotic 
liver FA profile is characterized by substantial reductions in long chain polyunsat rated 
FA (LC-PUFA) concentrations; specifically that of arachidonic acid (C20:4n-6) (Araya et 
al., 2004). While linoleic (18:2n-6) and α-linolenic (18:3n-3) are unaltered, the 
concentrations of eicosapentaenoic acid (EPA, C20:5n-3) and docosahexaenoic acid 
(DHA, C22:6n-3) are decreased (Araya et al., 2004).  The desaturation and elongation of 
linoleic and α-linolenic by desaturases (∆5-desaturase, ∆6-desaturase) and elongases 
(ELOVL-2, ELOVL-3) are involved in synthesis of LC-PUFA (Eder et al., 2002).  Trans-
10, cis-12 CLA inhibits both ∆5- and ∆6-desaturase in HepG2 cells (Eder et al., 2002).  A 
recent tracer study with [U-13C] linoleic acid showed significant reduction in n-6 PUFA 
synthesis by inhibition of elongation and desaturation in the liver homogenates of 
neonatal pigs (Lin et al., 2011). A decrease in arachidonic acid synthesis would alter 
eicososonoid metabolism and potentially reduce the synthesis of prostaglandin E2 (PGE2) 
(Sugano et al., 1998), which is known to have protective effects on the liver (Lukivskaya 
et al., 2001). 
Typical NAFLD is also characterized by increased n-6:n-3 LC-PUFA ratio which 
favors lipid synthesis over lipid oxidation and secretion, leading to hepatic lipid 
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accumulation (El-Badry et al., 2007).  Trans-10, cis-12 CLA reduces the n-3 PUFA in 
liver (Kelley et al., 2006; Kelley et al., 2009) in addition to arachidonic acid.  The n-3 
PUFA downregulate SREBP-1c and up-regulate PPAR-α, which regulates lipid oxidation 
(CPT1, ACOX1) and secretion (ApoB100).  A decrease in hepatic n-3 PUFA would not 
only reduce lipid oxidation but increase lipogenesis, leading to hepatic steatosis (El-
Badry et al., 2007). Although the trans-10, cis-12 CLA-induced responses in FA 
oxidation are variable in mice, consistently increased lipogenesis (Table 2.2) suggests a 
potential role for n-3 PUFA. On the contrary, CLA feeding increased n-3 PUFA content 
and decreased n-6 PUFA in the rat (Li and Watkins, 1998; Eder et al., 2005) which could 
explain the differences in CLA effects between the two species. Although the exact 
mechanism of CLA action has not been elucidated, it was suggested that the metabolites 
of CLA, conjugated dienes (CD)18:3, CD20:3, and CD20:4 could compete with other 
PUFA at the level of formation and metabolism in liver and affect LC-PUFA synthesis 
(Banni et al., 2004).  
CLA and SCD in hepatic lipid metabolism 
 
In the adipose, there are some similarities between the effects of trans-10, cis-12 
CLA and inhibition of SCD1.  For example., reduced adiposity is observed with both 
dietary trans-10, cis-12 CLA and SCD1 inhibition and one could speculate that the 
effects of trans-10, cis-12 CLA are mediated through SCD1 as trans-10, cis-12 CLA 
decreases SCD1 in adipose (Brown and McIntosh, 2003). However, a study with SCD1-/- 
mice showed that the anti-obesity effects of trans-10, cis-12 CLA were independent of 
SCD1 gene expression and enzyme activity (Kang et al., 2004).   
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 Unlike adipose, the effects of  trans-10, cis-12 CLA are varied in liver (Table 
2.2). While trans-10, cis-12 CLA decreased hepatic SCD activity in-vitro (Park et al., 
2000), in-vivo studies report increased hepatic SCD1 gene expression (Rasooly et al., 
2007; Guillen et al., 2009). In contrast to trans-10, cis-12 CLA effects in mice, SCD1-/- 
mice showed increased insulin sensitivity, reduced hepatic lipogenic genes, up-rgulated 
lipid oxidizing genes, increased hepatic saturated FA and unchanged hepatic n-3 nd n-6 
PUFA (Ntambi et al., 2002). SCD1-/- mice fed trans-10, cis-12 CLA showed reduced 
hepatic accumulation compared to wild-type mice (Kang et al., 2004) confirming that 
reduced SCD1 expression decreases hepatic lipid accumulation (MacDonald et al., 2008). 
Liver specific SCD1 knock-out decreased expression of SREBP1 and ChREBP and their 
target genes thereby reducing hepatic lipogenesis (Miyazaki et al., 2007).  In contrast, 
short-term inhibition of tissue specific hepatic SCD increased hepatic TG content and 
enhanced insulin signaling (Gutierrez-Juarez et al., 2006) but the long-term inhibitio  
decreased hepatic steatosis (Jiang et al., 2005). The differences in responses observed in 
liver-specific knock-out versus complete SCD knock-out mice suggest that hepatic lipid 
metabolism is being affected by lipid metabolism in non-hepatic tissues (Flowers and 
Ntambi, 2008). 
  As trans-10, cis-12 CLA effects in mice are mostly associated with insulin 
resistance, increased hepatic SCD1 expression is probably due to increased SREBP-1c 
expression.  Hepatic steatosis due to trans-10, cis-12 CLA is also seen in the absence of 
insulin and is associated with reduced expression of SCD1 and other lipogenic genes 
(Jourdan et al., 2009). These results indicate that the disturbances in hepatic lipid 
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metabolism caused by dietary t ans-10, cis-12 CLA are mediated by multiple 
mechanisms (House et al., 2005) rather than through changes in SCD1 alone.  
Effect of CLA on mammary lipid metabolism 
Among all the CLA isomers, the role of trans-10, cis-12 CLA has been 
extensively studied in relation to its effects on mammary lipid metabolism. Trans-10, cis-
12 CLA has been clearly established as a potent inhibitor of milk fat synthesis (Baumgard 
et al., 2000). Abomasal infusion of 10 g/d of trans-10, cis-12 CLA reduced milk fat yield 
by 43% while no effects were observed on other milk components (Kadegowda et al., 
2008). Similar findings were also observed with rumen-protected trans-10, cis-12 CLA 
supplemented over a period of 20 weeks (Perfield et al., 2002; Bernal-Santos et al., 
2003). 
The trans-10, cis-12 CLA is incorporated into milk fat and the transfer efficiency 
remains constant around ~22% across CLA dose ranges irrespective of a concomitant 
reduction of milk fat yield (de Veth et al., 2004). As a result of consistent uptake, the 
relationship between the dose of trans-10, cis-12 CLA and depression in milk fat yield is 
curvilinear (Bauman and Griinari, 2003). De veth et al.(2004) summarized data across 
experiments and demonstrated that a dose of trans-10, cis-12 CLA dose of 6 g/d produces 
a maximal response in milk fat reduction beyond which there is little decrease in milk fat 
synthesis (de Veth et al., 2004). The other major CLA isomer, cis-9, trans-11 CLA, has 







The effects of  trans-10, cis-12 CLA-induced MFD alter the pattern of milk FA 
composition, providing the insight about the mechanism for the decrease in milk fat yield 
and composition (Bauman and Griinari, 2003). The reduction in milk fat yield involves 
significant reduction in FA of all chain lengths (Chouinard et al., 1999; Baumgard et al., 
2002) however, the decrease in the yield of SMCFA are greater compared to LCFA 
(Chouinard et al., 1999; Bauman and Griinari, 2003) and the effects are pronounced at 
larger doses of trans-10, cis-12 CLA. Similar responses were observed in lactating mice 
although mouse milk has a lower proportion of denovo synthesized FA (Bauman et al., 
2011).  Thus trans-10, cis-12 CLA-induced alterations in milk FA composition and 
significant reductions in milk fat yield suggest that the mechanism may involve either 
reduced milk fat secretion and/or synthesis. Previous studies using pure CLA isomers 
indicate that milk fat synthesis is significantly reduced by trans-10, cis-12 CLA (Bauman 
et al., 2011). The infusion of trans-10, cis-12 CLA  was accompanied by dramatic 
reductions of mRNA abundance of enzymes involved in denovo FA synthesis (ACC, 
FASN), mammary uptake and intracellular transport of FA (LPL, FABP), desaturation 
(SCD) and triglyceride synthesis (GPAT, AGPAT)( Piperova et al., 2000; Peterson et al., 
2003). Lactation response to trans-10, cis-12 CLA is conserved across species including 
lactating rodents (Kadegowda et al., 2010). Similar findings were also observed invitro in 
bovine mammary cell line where mRNA abundance for ACC, FASN, SCD and FABP 
were reduced after 48 hours of incubation with trans-10, cis-12 CLA (Kadegowda et al., 
2009, Peterson et al., 2004).   
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The consistent and coordinated suppression of mammary lipogenesis in both dairy 
cows and lactating rodents suggests the involvement of a central regulator of lipid
synthesis. SREBP1c is the master regulator of mammary lipogenesis and mRNA 
abundance of its active nuclear fragment was decreased in response to trans-10, cis-12 
CLA in dairy cows (Harvatine and Bauman, 2006; Gervais et al., 2009), mice 
(Kadegowda et al., 2010) and bovine mammary epithelial cells (Peterson et al., 2004). 
Trans-10, cis-12 CLA can downregulate the nuclear abundance of SREBP-1 either by 
inhibiting proteolytic activation processing of SREBP-1 protein or inhibition of the 
SREBP-1 gene transcription (Bernard et al., 2008). The addition of trans-10, cis-12 CLA 
in bovine mammary epithelial cells had no effect on SREBP-1 mRNA. However, the 
abundance of the active nuclear fragment was reduced, suggesting reduced proteolytic 
activation of SREBP-1 precursor protein (Peterson et al., 2004). Similar findings were 
observed invivo (Loor et al., 2005). However, mammary expression of SREBP-1 was 
decreased both invivo (Harvatine and Bauman, 2006; Kadegowda et al., 2010) and invitro 
(Kadegowda et al., 2009). The extent of SREBP1 suppression is similar to the magnitude 
to the depression in milk fat yield during trans-10, cis-12 CLA-induced MFD (Gervais et 
al., 2009; Bauman et al., 2011). However the responses observed with SREBP1 
regulatory proteins like INSIG1 are not consistent (Harvatine and Bauman, 2006; 
Kadegowda et al., 2010). 
Dosage effect 
The trans-10, cis-12 CLA dose used in rodent studies ranged between 0.3-1 
percent to obtain maximum MFD, compared to 0.05% in dairy cows (Bauman et al., 
2011). Larger doses of trans-10, cis-12 CLA in dairy cows have been shown to cause 
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generalized reduction in all milk component yield and dramatic increase in somatic cell 
count (Bell and Kennelly, 2003). Similar responses were observed in mice where larg  
doses (0.5%) negatively affected mammary development as it reduced ductal elong tion 
and caused premature alveolar budding (Foote et al., 2010). These effects were associated 
with increased expression of inflammatory markers suggesting detrimental effects with 




Table 2.1. Studies showing trans-10, cis-12 CLA-induced changes in body, adipose and 
liver weights and liver lipid concentration (Number of observations (mean percent 
change) 










Increase - - 24(92) 19(515) 
Decrease 21(31) 2 29(666) - - 
No change 16 - 2 2 
      
Rats3 
Increase - - - 1(25) 
Decrease - 1(23) - 4(19) 
No change 11 3 8 4 
      
Hamsters4 
Increase - - 8(20) - 
Decrease 2(14) 11(20) - 3(37) 
No change 11 2 2 5 
      
Humans5 
Increase - - - - 
Decrease 2 6 - - 
No change 11 13 - - 
2Studies used:(Andreoli et al., 2009, Belury and KempaSteczko, 1997, Clement et al., 
2002, Degrace et al., 2004, Degrace et al., 2003, DeLany and West, 2000, Foote et al., 
2010, Halade et al., 2009, 2010, Ide, 2005, Jourdan et al., 2009, Kadegowda et al., 2010, 
Kelley et al., 2009, Liu et al., 2007, Nakanishi et al., 2004, Park et al., 1997, Park et al., 
1999a, Park et al., 1999b, Poirier et al., 2005, Poirier et al., 2006, Rasooly et al., 2007, 
Takahashi et al., 2003, Tsuboyama-Kasaoka et al., 2000, Yanagita et al., 2005) 
3Studies used:(Andreoli et al., 2007, Choi et al., 2004, Moya-Camarena et al., 1999, 
Purushotham et al., 2007, Tsuzuki et al., 2004) 
4Studies used: (Bissonauth et al., 2006, de Deckere et al., 1999, Lasa et al., 2011, 
Macarulla et al., 2005, Miranda et al., 2009, Navarro et al., 2009, Simon et al., 2006, 
Tarling et al., 2009, Zabala et al., 2006) 
5Studies used :(Basu et al., 2000, Benito et al., 2001, Berven et al., 2000, Gaullier et al., 
2005a, Gaullier et al., 2005b, Kamphuis et al., 2003, Kreider et al., 2002, Malpuech-
Brugere et al., 2004, Moloney et al., 2004, Mougios et al., 2001, Petridou et al., 2003, 
Racine et al., 2010, Riserus et al., 2002, Riserus et al., 2004, Taylor et al., 2006, Thom et 




Table 2.2. Studies showing trans-10, cis-12 CLA-induced changes in hepatic gene expression and circulating levels of insulin, 
adipokines and TNF-α. Genes are classified based on their ascribed function (↑, ↓, ↔; increase, decrease or no changes 
respectively)  
  Mice1 Rats2  Hamsters3 
  ↑ ↓ ↔ ↑ ↓ ↔ ↑ ↓ ↔ 
Lipogenesis 
  ACC 5(126)4 - 1 - - - 1(99) - 1 
  FASN 7(243) - 1 - 1(50) 2 - - 2 
  SCD1 2(150) - 3 - 1(80) - - - - 
  SREBP1 3(53) - 2 - 1(40) 4 - - 3 
  PPAR-γ 2(200) - - - - 2 - - - 
  ME 5(205) - - - - - - - - 
FA uptake, secretion and oxidation 
  CPT1 4(107) 1(59) 1 - - - - - 2 
  ACO 5(117) - 1 2(130) - 4 - - 2 
  PPAR-α - 1(53) - 1(125) - - - - 3 
  FAT/CD36 3(533) - - - - - - - - 
  LPL - - 1 - - - - - 1 
Insulin, adipokines, and TNFα 
  Insulin   12(2492) 1(29) 3 - - 3 - - 1 
  Adiponectin - 6(77) 5 - - - - - - 
  Leptin - 10(71) - - - 1 - - - 
  TNF-α - 4(32) 1 1(44) 2 - - - 
1 Studies used: (Clement et al., 2002, Degrace et al., 2003, Guillen et al., 2009, Ide, 2005, Jourdan et al., 2009, Kadegowda et 
al., 2010, Lin et al., 2004, Liu et al., 2007, Rasooly et al., 2007, Takahashi et al., 2003, Yanagita et al., 2005) 
2 Studies used:(Choi et al., 2004, Moya-Camarena et al., 1999, Purushotham et al., 2007, Stringer et al., 2010, Tsuzuki et al., 
2004) 
3Studies used :(Lasa et al., 2011, Macarulla et al., 2005, Miranda et al., 2009, Tarling et al., 2009) 
4Number of observations (mean percent change)
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Table 2.3. Summary of literature studies on amelioration of CLA-induced hepatic steato is 
% Added Dietary CLA  





Treatment     
Dose, %1 Observations 
        Nagao et al., 2008 3 - 6 28 2.0 0.95 Leptin  5 µg/d ↓ Hepatic steatosis,  
↑ Insulin sensitivity, 
Tsuboyama-
Kasaoka et al., 
2000 
5-14 30 1.0 0.72 Leptin 5 µg/d ↑ Insulin sensitivity,  
Ameliorated hepatic steatosis 
Purushotham et al., 
2007 
5 28 1.5 0.60 Rosiglitazone 10 mg/kg 
BW 
↑ Insulin sensitivity,  
Prevented depletion of 
epididymal 
 adipose tissue 
Liu et al., 2007 10 42 2.0 1.00 Rosiglitazone 10 mg/kg 
BW 
↓ Hepatic TG content, 
↓ Hepatic lipogenesis, 
↑ Serum leptin and 
adiponectin,  
 Prevents lipodystrophy 
Oikawa et al., 2009 7 28 3.0 0.98 Arachidonic 
acid 
1, 2 ↓ Induction of hepatic 
steatosis, 
↑ liver PGE2, 
↑ Epididymal adipose 
Nakanishi et al., 
2004 
7 28 - 1.20 γ –Linoleic 
acid 
5 ↓ Hepatic steatosis, 
↑ PGE2  
Kelley et al., 2009 10 56 - 0.50 Flax seed oil 
(α-Linoleic 
acid) 
0.39 ↓ Steatosis, 
↑n-3 and n-6 PUFA in liver  
Ide, 2005 7 - 8 22 1.0 0.50 Fish Oil 1.5,3,6 ↑ Leptin and Adiponectin,  
↓ Insulin, ↓ TG in liver,  
↑ Fat pad 
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Ferramosca et al., 
2008 
 
10 105 1.0 0.50 Pine oil 7.5 Serum insulin levels stabilized 
 over 3 weeks 
Tsuboyama-
Kasaoka et al., 
2003 
5 - 6 100 1.0 0.35 34% Dietary 
fat 
 Normal plasma insulin levels, 
↑ Liver weight 
Yanagita et al., 
2005 
6 28 2.0 0.74 DHA 0.5 ↓ Fatty liver, ↓ FA synthesis, 
 Plasma leptin and 
Adiponectin  
unaffected 
Vemuri et al., 2007 10 56 - 0.50 DHA, EPA  0.5, 0.5 Prevented hepatic steatosis,  
Partially restored plasma 
leptin,  
Only DHA restored plasma  
adiponectin 














Figure 2.3. Current concepts in the pathways of trans-10, cis-12 CLA-induced hepatic 
steatosis 
1. Adipose tissue lipodystrophy caused by increased proinflammatory cytokines and 
reduced adipokines leading to higher circulatory levels of free FA (FFA). 2. 
Hyperinsulinemia induced by systemic insulin resistance. 3. Alterations in hepatic lipid 
metabolism leading to hepatic steatosis. 4. Alterations in hepatic FA composition. 
SREBP1c, Sterol regulatory element binding protein; PPAR-γ, Peroxisome proliferator 
activated receptor- γ; TNF-α, Tumor necrosis factor-α; IL-6, Interleukin-6; IL-8, 
Interleukin-8; PEPCK, Phospho-enol pyruvate carboxykinase; G6P, Glucose 6-
phosphatase; ChREBP, Carbohydrate response element binding protein; PPAR-α, 










































Short-and medium-chain fatty acids (SMCFA) 
 While milk FA composition is different for every species, the pattern of FA 
composition must allow milk fat secretion at body temperature (Parodi, 1982; Dils, 
1983). Ruminant milk is characterized by greater proportions of SMCFA (~50%) 
(Jensen, 2002) and may reflect the relative absence of PUFA. The physiological 
significance of SMCFA might be to maintain fluidity and to regulate the melting 
temperature of milk fat (Barbano and Sherbon, 1980). In addition, short-chain FA 
(SCFA) including acetate, propionate and butyrate are the major source of energy in 
ruminants, providing up to 80% of their maintenance energy requirements (Bergman, 
1990). Propionate serves as a major precursor for glucose (Huntington et al., 1981), while 
acetate and butyrate are utilized for lipogenesis in adipose and mammary tissues. This 
contrasts with other species where glucose serves as the carbon source for SMCFA for 
denovo FA synthesis. In addition to energetic and nutritional contribution of SCFA, 
medium-chain FA (MCFA) including C12 and C14 have a strong potential in suppressing 
ruminal methanogenesis (Blaxter and Czerkaws, 1966).   
  Dietary SMCFA might play an important role during milk fat synthesis. As 
reviewed earlier, during MFD the proportions of SMCFA are reduced to a greater extent 
than LCFA, underscoring the importance of SMCFA in maintaining milk fat yield. 
Recently, abomasal infusion of butterfat, used as source for SMCFA, increased milk fat
content and yield in lactating dairy cows even under normal conditions of milk fat 
synthesis (Kadegowda et al., 2008). To appreciate the role of SMCFA on milk fat 




Absorption and metabolism of SMCFA 
Triglycerides containing SMCFA possess distinct physical and chemical 
properties characterized by low melting point, small molecular weight and w ter soluble 
properties which make their absorption and metabolism different from the TG containing 
LCFA (Dils, 1983; Marten et al., 2006).  
 
 
Figure 2.4. Transport, distribution and metabolic fate of exogenous FA according to their 
chain length (Bach et al.,1996) 
 
In monogastric animals, pancreatic lipase completely hydrolyzes TG containing   
SMCFA, which further are transported directly to the liver via the portal vein as FA or 
monoglyceride (MG) and are preferentially metabolized as an energy source. SMCFA are 
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also more ketogenic than LCFA (Marten et al., 2006). The liver is able to produce ten 
times more CO2 with C8 than with C16, which may exceed the capacity of liver Krebs 
cycle, directing acetyl-CoA towards ketone body formation (Bach and Babayan, 1982). 
On the contrary, pancreatic lipase incompletely hydrolyzes LCFA from TG resulting in 
the formation of LCFA, MG and DG. In addition, LCFA are absorbed by the intestial 
mucosa, are incorporated into chylomicron TG, and reach the systemic circulation vi  the 
lymph system and preferentially get distributed to peripheral tissues before being utilized 
in liver (Bach and Babayan, 1982). 
In ruminants, the short-chain VFA are produced by the anaerobic microbial 
fermentation of carbohydrates. The net absorption of VFA is dependent upon their 
concentration in rumen and amounts metabolized by the rumen wall. The rates of 
utilization by the rumen wall are butyrate > propionate > acetate (Stevens and Stettler, 
1966; Kirat et al., 2006). Recently, the role of monocarboxylate transporter-1 (MCT-1) 
was demonstrated in the transepithelial transport and efflux of VFA across rumen 
epithelium towards the blood side (Kirat et al., 2006). Metabolic use of MCFA are not 
documented in dairy cows. However, greater intestinal digestibilities and reduced transfer 
efficiency of C12:0 and C14:0 in milk fat as compared to other LCFA (Dohme et al., 
2004) suggest ruminal absorption and extensive hepatic utilization of the MCFA.   
Milk fat responses to supplemental SMCFA 
Milk fat responses to supplemental SMCFA are not well documented. Among 
earlier studies, Storry et al. (1969) observed milk fat responses to intravenous infusion of 
short-and medium-chain TG. Milk fat content and yield were significantly greate  with 
C6, C12 and C14 TG, while no effects were observed for other short-chain TG. This was 
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probably due to extensive catabolism in extra mammary tissues. Further studis with 
individual MCFA (C12 and C14) showed inconsistent milk fat responses. Milk fat yield 
was significantly reduced with C14:0 (Steele and Moore, 1968; Odongo et al., 2007) 
while no effect was observed in others (Dohme et al., 2004; Hristov et al., 2011). 
Similarly, milk fat yield was reduced with C12:0 in some studies (Steele and Moore, 
1968; Hristov et al., 2011,) while no effect was observed in others (Dohme et al., 2004). 
Coconut oil (CO), a rich source of C12 and C14 FA, was used at increasing levels in diet 
of lactating dairy cows but no effects were observed on milk fat content and yield (Storry 
et al., 1971). On the contrary, significant differences were observed in milk fat respons s 
between unprotected and protected CO (Storry et al., 1974; Astrup et al., 1976). The 
protected form of CO not only improved rumen fermentation parameters but also 
increased milk fat content and yield as compared to unprotected CO (Storry et al., 1974; 
Astrup et al., 1976).  
A recent invitro study in mammary epithelial cell lines showed that SMCFA (C4, 
C6 and C8) reduce ACC enzyme activity and increased the expression of CD36 and 
PPAR-γ (Yonezawa et al., 2004). Octanoate (C8) stimulated the TG accumulation in a 
concentration-dependent manner and increased lipid droplet formation (Yonezawa et al., 
2004). The inhibitory effects of C6 and C8 on hexokinase and phosphofructokinase and 
of C10 on pyruvate dehydrogenase enzyme further reflect the inhibitory effects of SCFA 
on milk fat synthesis (Heesom et al., 1992).    
In lactating rats, MCT (medium-chain triglycerides, C8 and C10 reduced the rate 
of mammary lipogenesis by 82% (Agius and Williamson, 1980) and 57% (Souza and 
Williamson, 1993). Energy intake was also low due to rapid removal and hepatic 
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oxidation of MCFA, resulting in formation of ketone bodies, signaling a decrease in food 
intake.   
The transfer efficiency of SMCFA into milk fat is very low as these FA are 
predominantly absorbed directly in the hepatic portal vein in contrast to LCFA which are 
mostly incorporated in to lipoprotein lipids and released in lymph (Grummer, 1991). 
Among SMCFA, the transfer efficiency of short-chain FA including C6 to C10 is 
minimal (Storry et al., 1969; Grummer and Socha, 1989) and dietary supplementation is 
not useful for increasing these FA in milk. However, C12 and C14 are transferred with 
relatively greater efficiency. The C12 represents the borderline in chain length where 
absorption shifts from rumen to intestine (Dohme et al., 2004). The transfer efficiency of 
C12 ranges between 18-26% (Rindsig and Schultz, 1974; Dohme et al., 2004; Hristov et 
al., 2009). The transfer efficiency of supplemented C14 is variable. While some have 
shown transfer efficiency in the range of 12-15% (Odongo et al., 2007; Hristov et al., 
2009) others have shown greater transfer efficiency (39%) (Dohme et al., 2004). Similar 
findings were observed in rats where the transfer efficiency of C8 and C10 were less, as 






Hypothesis and study objectives 
 Based on the above literature the central hypothesis of the dissertation is 
“ the availability of denovo synthesized FA is the key limiting substrate for milk fat 
synthesis”. Following were the study objectives to test this hypothesis: 
1. To determine the milk fat response to dietary supplementation of SMCFA in 
lactating dairy cows. 
2. To determine the effects of increased availability of SMCFA during CLA-induced 
MFD on mammary lipid metabolism.   
3. To study mammary and hepatic lipid metabolism in response to a PPAR- γ agonist 
during CLA-induced MFD in lactating mice.  
The following figures summarize the milk fat synthesis process and the 
experimental approaches used to test the hypothesis.
 
Figure 2.5. The basics of milk fat synthesis (Modified from Baumgard, L. H., 2002)  
 




























Figure 2.6. The experimental approaches used to test the potential limitation of de ovo 
synthesized fatty acids for milk fat synthesis (Modified from Baumgard, L. H., 2002) 
1. To determine the milk fat response to dietary supplementation of SMCFA in lactating 
dairy cows. 
2. To determine the effects of increased availability of SMCFA during CLA-induced 
MFD on mammary lipid metabolism.   
3. To study mammary and hepatic lipid metabolism in response to a PPAR- γ agonist 
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Chapter 3: EXPERIMENT 1 
 
Milk fat responses to dietary supplementation of short-and medium-chain fatty 
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Short-and medium-chain fatty acids (SMCFA), which are synthesized denovo in the 
mammary gland, are reduced to a much greater extent than the long-chain fatty acids 
during diet-induced milk fat depression.  Our hypothesis was that SMCFA are limiting 
for milk fat synthesis even under conditions when milk fat is not depressed.  Our 
objective is to test the potential limitation of SMCFA on milk fat synthesis via diet ry 
supplementation. Sixteen lactating Holstein cows (107 ± 18 DIM) were fed a corn silage-
based total mixed ration. Cows were randomly assigned to groups of 4 per pen and 
supplemented with one of 4 dietary fat supplements (600g/d) supplied in a 4x4 Latin 
square design with 21-d experimental periods. Treatments consisted of fat supplements 
containing mixtures of calcium salts of long-chain fatty acids (Megalac®; M) and a 
SMCFA mixture (S) (C8- 3.3%, C10- 7.6%, C12- 9.85%, C14- 32.12% and C16- 
47.11%) that contained  0, 200, 400, and 600 g/d S substituted for M (S0, S200, S400, 
and S600, respectively). No treatment effects were observed for dry matter intk , and 
fat-corrected milk. However, milk yield was linearly reduced with S600. Milk fat 
increased linearly by 0.17, 0.25, and 0.33 percentage units for the respective S treatments.  
However, fat yield peaked at S200 and milk protein concentration and yield was 
significantly reduced at the higher S levels due to a linear trend towards reduced milk 
yield in the S600 treatment.  In conclusion, SMCFA supplementation linearly increased 
milk fat concentration but reduced milk production at the higher levels of 





 In 2000, the USDA Federal Milk Marketing System adopted a multiple 
component pricing (MCP) system that changed the milk payment system for dairy 
producers to one based primarily on the amounts of milk components produced rather 
than milk volume.  Among the milk components, milk fat and milk protein are the most 
valuable as compared with other solids (lactose and minerals) (USDA-NASS, 2009).  
Milk fat responses to dietary manipulations are large as compared to other milk 
components (Sutton, 1989).  This signifies the importance of understanding the metabolic 
regulation of milk fat synthesis.  In turn, understanding regulation of milk fat synthesis 
would further help in developing practical guidelines for dairy farmers to better control 
the quality and quantity of milk fat produced in relation to market demands.   
Milk fat consists primarily of triglycerides (TG) which include a glycerol 
backbone and three ester-linked FA.  The basic mechanism of milk fat synthesis depends 
on two general sources of FA; i.e. denovo FA synthesis in the mammary gland, and 
transfer of preformed FA from TG in the blood.  The SMCFA including FA from C4-C1  
and half of C16 are synthesized denovo while LCFA either originate from diet or are 
mobilized from adipose TG as preformed FA (Moore and Steele, 1968).  Dietary 
manipulations can reduce milk fat by 46% (Piperova et al., 2000).  During diet-induced 
milk fat depression (MFD) the proportion of denovo synthesized FA are reduced to a 
much greater extent than LCFA (Banks et al., 1984; Loor and Herbein, 1998). The 
alterations in FA composition are attributed to reduced acetyl-CoA carboxylase (ACC), a 
rate limiting enzyme for denovo FA synthesis (Mellenberger et al., 1973), and fatty acid 
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synthase (FAS) enzyme activity (Piperova et al., 2000). Under these situations denovo 
FA synthesis might be limiting for milk fat synthesis and the provision of dietary 
SMCFA in the proportion of denovo synthesized FA might rescue MFD. However, 
abomasal infusion of butterfat, used as a source of SMCFA, increased milk fat yeld even 
under normal conditions of milk fat synthesis (Kadegowda et al., 2008). This led to our 
hypothesis that SMCFA might be limiting even during normal conditions of milk fat 
synthesis. The objective of our experiment was to test the potential limitation of SMCFA 
by dietary supplementation of a FA mix containing SMCFA in incremental doses and 
observing their effects on milk fat responses in lactating dairy cows. 
MATERIALS AND METHODS 
 
Animals, Experimental Design, and Treatments  
All procedures for this experiment were conducted under a protocol approved by 
the University of Maryland Institutional Animal Care and Use Committee. Sixteen 
Holstein dairy cows in mid lactation (107 ± 18 DIM) were used in 4x4 Latin square 
design balanced for carry over effects. Treatments were as follows: 1) S0 - Fed basal diet 
with 600 g/d of Megalac (M); 2) S200 - Fed basal diet with 400 g/d M and 200 g/d 
SMCFA mix (S); 3) S400- Fed basal diet with 200 g/d M and 400 g/d S; and 4) S600- 
Fed basal diet with 600 g/d of S and no M.  
The dietary S consisted of a mixture of C8, 3.3 %; C10, 7.6 %, C12, 9.9 %; C14, 
32.1 % and C16, 47.1 % as free FA (Sigma-Aldrich, St. Louis, MO) corresponding to the 
proportions of denovo synthesized FA in milk fat. Short-chain FA including C4 and C6 
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could not be added in the FA mixture because of their volatile nature. The fat 
supplements were thoroughly mixed with concentrates before being incorporated into the 
basal diet to ensure homogenous mixing.  The relative proportions of FA in S are shown 
in Figure 3.1.  
Experimental Procedure 
Experimental periods were 3 wk. Control diet was fed during the first week of 
each period to reduce carryover effects. This was followed by 2 wk of treatment diets. 
Four cows were randomly allotted to each pen which included access to sawdust bedded 
freestalls. All cows within each pen were group fed. The basal diet contained 56% forage 
and 44% concentrate (DM basis) to meet NRC (2001) nutrient specifications for a 600-kg
cow producing 40 kg of milk containing 3.7% milk fat and 3.1% milk protein.  Ingredient 
and chemical composition of the basal diet is given in Table 3.1. Forage and ingredient 
DM were measured weekly, and the TMR was adjusted accordingly to maintain a 
constant forage-to-concentrate ratio on a DM basis.  Amounts of feed offered and refused 
were recorded once daily at 0800h.  
Milk Sampling and Component Analysis 
 Cows were milked twice daily at 0700 and 1700 h, and milk production was 
recorded using automated milk recording system at each milking. Two sets f milk 
samples were collected from the last 6 consecutive milkings of wk 3 of each experimental 
period.  One set was collected with preservative for milk fat, protein, and somatic cell 
count (SCC) analysis by infrared analysis (Foss Milk-O-Scan, Foss Food Technology 
Corp., Eden Prairie, MN) and milk urea nitrogen (MUN) 
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by direct chemical analysis (Bentley Chemspec, Bentley Instruments, Inc., Chaska, MN).  
A second set of milk samples were composited and frozen at -20oC for subsequent 
analysis of individual FA. 
FA Composition 
 Milk fat was extracted using a modified Folch procedure (Christie, 1982). The FA 
methyl esters (FAME) were prepared by mild transesterification with 1.4 mol/L of H2SO4
 
in methanol (Christie, 1982). The FAME were analyzed using an Agilent 5890 GC 
(Agilent Technologies, Santa Clara, CA) equipped with a Supelco 2560 capillary column 
(30 m x 0.25 mm id, Supelco, Bellefonte, PA) and a flame ionization detector. The 
column was maintained at 150°C for 5 min followed by ramp of 1.6oC/min to 180oC, then 
at 1.4oC/min to 190oC and finally holding the temperature at 190oC for 10 min. Nitrogen 
was used as carrier gas with a linear velocity of 25 cm/s and split ratio of 1:100. The 
injection port and etector were maintained at 250°C. Detector airflow was 222 mL/min, 
and hydrogen flow was 36 mL/min. Helium make-up gas was used at 80 mL/min. 
Individual FA and 18:1 isomers were identified using GLC-463 standard mixture (Nu-
Chek Prep Inc., Elysian, MN).   
 Short-and medium-chain FA were analyzed as butyl esters (FABE), which were 
mathematically converted to FAME and normalized to the FAME chromatogram (Gander 
et al., 1962). The original FABE procedure was modified as follows. Milk samples were 
heated in screw-capped test tubes at 80oC for 1 h in the presence of 1.4 N H2SO4
 in 
butanol followed by extraction with hexane in the presence of saturated KCl and distilled 
water. Samples were then centrifuged at 500 x g for 5 min at room temperature.  An 
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aliquot of the upper hexane layer was injected directly into a Hewlett-Packard 5880 gas 
chromatograph equipped with a split injector, a flame ionization detector, and a 25 m x 
0.2 mm fused silica capillary column coated with HP1 (Hewlett Packard, Avondale, PA). 
Helium was used as the carrier gas at a flow rate of 2 mL/min with a split ratio of 45:1. 
Injector and detector temperatures were set at 250°C, while column temperature st rted at 
130°C. Ramp was set at 6oC/min to 290oC, followed by 4oC/min to 260oC and finally 
holding at 260oC for 20 min. Standard mixtures, including GLC-60 (Nu-check Prep, Inc., 
Elysian, MN) were converted to FABE to aid in the identification and quantification of 
components. 
Statistical Analysis 
 Dry matter intake, milk production, milk components, and milk FA composition 
data for cows within each pen were summarized by experimental week and the pen 
average per cow from wk 3 was used as the experimental unit in the statistical analyses 
(SAS, Version 9.2, SAS Institute, Cary, NC). Transfer efficiency of individual FA were 
calculated as FA output in milk divided by the FA intake.  The statistical model included 
treatments as fixed effects, whereas pen and period were used as random effects. 
Treatment effects were tested using linear and quadratic orthogonal contrasts.  
Significance for all effects was declared at P ≤ 0.05.   
RESULTS 
The nutrient composition of the TMR and FA profile of individual dietary 
ingredients are presented in Tables 3.1 and 3.2, respectively. The total amount of dietary 
fat supplemented with the basal diet was 509, 539, 569 and 599 g with S0, S200, S400, 
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and S600 treatments, respectively (Table 3.3). The differences reflect substitution of free 
FA for Ca salts of FA in Megalac®. The treatments were designed to provide increasing 
amounts of SMCFA including C8, C10, C12 and C14 while keeping C16 constant in all 
groups. 
Production responses to fat supplement treatments are shown in Table 3.4. 
Treatments had no detectable effects on DMI, NEL intake, and 3.5% FCM.  However, 
there was a linear reduction (P < 0.03) in milk yield with increasing S. Milk production 
efficiency (3.5% FCM/DMI) was linearly increased with S treatments, reflecting a 
combination of the small but nonsignificant decreases in DMI, and increases in 3.5% 
FCM that were observed with S200 and S600 relative to S0.  
 Milk fat content increased linearly in a dose-responsive manner by 4, 7, and 9% 
with S200, S400, and S600, respectively (P < 0.05). Milk fat yield was numerically 
higher with S treatments and peaked at S200 (1,709 g/d). However, the differences were 
not significant (P = 0.28). Milk protein content and yield increased with S200 (3.12%, 
1,373 g/d) but were linearly (P < 0.01) reduced at higher S levels (S400 and S600). 
Concentrations (g/100 g of FAME) and yield (g/d) of individual FA in milk are 
shown in Tables 3.5 and 3.6, respectively. The content of individual short-chain FA 
(SCFA, C4-C12) were not altered. However the proportions of medium-chain FA 
(MCFA) were increased with S treatment. Myristic acid (C14) content was increased (P < 
0.001) by 8, 19, and 26% and yield was increased by13, 24 and 32% with S200, S400 and 
S600 respectively. Myristoleic acid (C14:1) concentration also increased (P < 0.01) 
linearly with S treatment. Palmitic acid (C16) concentration was increased (P < 0.01) by 
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5 and 7% with S400 and S600, respectively. However the yields of C16 were not 
affected. Total C18 content was reduced (P < 0.01) by 13 and 24% at higher S levels 
(S400, S600). Further, total C20 FA content was reduced (P < 0.01) by 24 % with S600.  
Total saturated FA content was increased (P < 0.001) by 6% while monounsaturated FA 
(MUFA) were reduced by 10 and 12% (P < 0.001) with S400 and S600, respectively.  
The transfer efficiencies for different SMCFA are shown in Figure 2.2. The 
transfer efficiencies were 15.2, 15.9, and 1.4 for C8; 19.3, 2.9, and -2.1 for C10; 28.7, 
16.7, and 11.2 for C12:0; and 34.6, 31.9, and 28.4 for C14:0 for S200, S400, and S600, 
respectively. These values were calculated as the amount of FA excreted in the milk fat 
expressed as the percentage of the amount added to the TMR by subtracting the SMCFA 
treatment yields from the S0 treatment.   
DISCUSSION 
The purpose of this study was to evaluate the potential limitation of SMCFA on 
milk fat synthesis in lactating dairy cows. Treatments included incremental amounts of 
SMCFA substituted for M to keep diets isolipidic. However, the actual amounts of fat 
supplemented varied with each treatment due to differences in the FA content of 
individual supplements (85%, M; 98%, C8; 97%, C10; 98%, C14; 99%, C16). Never-the-
less, the differences were not large enough to significantly change the interpretation of 
data.  In addition, as desired the amount of SMCFA supplemented increased, whereas 
C16 intake was constant in all diets.  
The DMI was similar for all treatments but was 1 kg/d less in the S600 treatment. 
While the effects of SCFA on feed intake are not well documented, MCFA can reduce 
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feed consumption when supplemented at high dietary concentrations. For instance DMI 
was significantly reduced with lauric acid supplemented at 4% of diet DM (Dohme et al., 
2004).  Increased feed refusals were also reported by feeding myristic ac d at 5% of diet 
DM (Odongo et al., 2007) and with coconut oil (CO) containing higher concentrations of 
lauric and myristic acid (Storry et al., 1974). Medium chain FA was shown to disrupt 
rumen metabolism by reducing the number of protozoa, depressing fiber degradability, 
and subsequently depressing intake (Dohme et al., 2001). However, due to low dietary 
proportions of MCFA in the present study, significant interaction with the rumen 
microbes can likely be ruled out as the amount required to disrupt microbial populatin is 
thought to be 4% of DMI when MCFA are supplemented with a TMR (Hristov et al., 
2009). The milk yield for high-producing dairy cows is limited by DMI (Allen, 2000). 
Therefore, the numerical reduction in milk yield and 3.5% FCM at higher S levels might 
reflect the nonsignificant decrease in DMI. A similar response was observed in dairy 
cows with intraruminal infusion of lauric acid and CO (Hristov et al., 2009).  
Milk Fat and FA Composition 
Previous studies have reported variable milk fat responses to individual SMCFA 
supplemented either as TG or free FA. Intravenous infusion of TG containing SCFA (C3, 
C4, C6, C8, C9, and C10 showed no changes whereas infusion of MCT increased milk 
fat yield (Storry et al., 1969). Similarly MCFA either reduced (Hristov et al., 2011) or 
showed no effect (Hristov et al., 2009) on milk fat yield. Similarly CO either mp oved 
(Storry et al., 1971) or had no effect (Hristov et al., 2009) on milk fat yield. Astrup et al., 
(1978) found that rumen-protected coconut oil increased milk fat percent, however, 
unprotected CO decreased fat percent.  Milk fat output was improved in the present study 
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although the effects were not significant. This effect is probably not related to energy 
consumption as energy intake was similar among all the treatments. Effects o  SMCFA 
are more apparent when the yields of individual FA are considered. The yield and content 
of SCFA were maintained and MCFA were increased with S treatments. The availability 
of palmitic acid was similar for all treatments, however, its secretion numerically 
improved with S treatments. This effect could be attributed to chain elongation of dietary 
SMCFA as similar response was observed with intravenous infusion of TG containing 
SCFA (Storry et al., 1969). The availability of SMCFA along with palmitic ac d can 
affect milk TG synthesis (Hansen and Knudsen, 1987).    
 Milk fat is comprised of 95-98% TG (Jensen, 2002) and mammary TG synthesis 
involves FA esterification on 3 carbons of the glycerol backbone. Palmitic acid is an 
important precursor for initiating acylation at the sn-1 position, forming sn-1 
lysophosphatidic acid (Hansen and Knudsen, 1987), which subsequently can be used as a 
substrate for myristyl-, oleoyl-, and stearoyl-CoA acylation (Kinsella and Gross, 1973).  
Short-chain FA are required for the rate-limiting step of esterification at the sn-3 position 
which is catalyzed by diacylglycerol acyl transferase (DGAT) (Parodi, 1979) The 
increased availability of palmitic acid might have increased incorporation of SMCFA 
during TG synthesis as reflected in milk fat composition with higher yield of denovo 
synthesized FA (DNFA). However, the responses were not significant due to reduced 
milk yield at higher levels of SMFCA supplementation. The yield of other LCFA 
including C18 and C20 may have been reduced due to dietary supply as a result of 
substitution of S for Ca salts of FA or substrate competition with SMCFA during TG 
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synthesis (Storry et al., 1969).  The increased myritstoleic acid yield suggests increased 
mammary stearoyl-CoA desaturase activity with S treatments (Hri tov et al., 2011).   
Transfer Efficiency 
Calculated apparent transfer efficiencies of individual FA are affected by their 
absorption and metabolism. The lower transfer efficiency of SCFA observed at higher 
levels of supplementation might be due to its preferential utilization by extra-mammary 
tissues.  Short-chain FA can be absorbed directly from the digestive tract into the p rtal 
vein and can be preferentially oxidized in the liver (Souza and Williamson, 1993). 
Previous reports in mice and dairy cows have shown extensive hepatic oxidation and 
reduced incorporation of C8 and C10 in extra hepatic tissues (Lavau and Hashim, 1978; 
Storry et al., 1969; Souza and Williamson, 1993).  Among the MCFA, 11-28% of dietary 
lauric acid was transferred in milk fat. This transfer efficiency is comparable to previous 
reports showing either 18% (Hristov et al., 2009) or 24-26% (Rindsig and Schultz, 1974; 
Dohme et al., 2004) of dietary lauric acid secreted in milk. Dietary myristic acid was 
transferred to milk at a rate between 28 and 35%, which is consistent with 39% reported 
previously (Dohme et al., 2004). However, these efficiencies are much greater than those 
reported by Hristov et al. (2009) and Odongo et al. (2007) of 15% and 12%, respectively. 
The reasons for such discrepancies are not clear. However, the amounts of C14 
supplemented were much higher in previous studies (Odongo et al., 2007; Hristov et al., 
2009), which might have reduced transfer efficiency due to extramammary utilization of 




 This is the first animal trial studying the effects of increasing amounts of dietary 
SMCFA on milk fat synthesis. Results indicate that increasing SMCFA linear y increased 
milk fat percentage.  However, no effect was observed for milk fat yield due to depressed 
DMI and reduced milk yield.  Further research is required to determine the mechanism by 
which these FA affect milk fat synthesis under conditions where DMI is maintained.  
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Table 3.1. Ingredient and chemical composition of the basal diet fed to lactating cows 
Item DM % 
Ingredient  
Corn silage 36.71 
Alfalfa Hay 19.59 
Corn grain, Ground 19.21 
Citrus pulp 4.66 
Soybean meal 16.22 
Corn gluten meal (60%) 0.35 
Limestone 0.73 
Calcium phosphate 0.42 
Magnesium oxide 0.17 
Sodium bicarbonate 0.59 
Potassium bicarbonate 0.11 
Dynamate 0.11 
Salt 0.39 






CP, % 15.71 
RUP, % 36.622 
ADF, % 21.51 


















      1Trace mineral and vitamin mix combined which provided an additional 0.76 mg/kg Co, 
10 mg/kg Cu, 5.5 mg/kg Fe, 0.64mg/kg I, 37 mg/kg Zn, 0.33 mg/kg Se, 3,526 IU/kg 
vitamin A, 1,175 IU/kg vitamin D, and 22 IU/kg vitamin E to the diet DM. 2Calculated 
value based the estimated TDN from feed analysis at 3X maintenance intake using NRC 
(2001) prediction equations.   
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Table 3.2. Fatty acid composition of different feed ingredients 








                                           g/100 g of FAME1 
12:0 2.19 0.57  0.06 0.43 
12:1 0.95 0.51    
13:0 0.39 0.33    
13:1 0.34 0.32    
14:0 0.71 0.83 0.07 0.17 0.51 
14:1 0.81 0.61    
15:0 0.46 0.26  0.08 0.13 
15:1 0.28 0.26   0.17 
16:0 19.71 22.43 13.62 18.15 26.01 
16:1 1.79 3.03 0.14 0.11 0.82 
17:0 0.31 0.47 0.08 0.17 0.32 
17:1 0.52 0.69   0.18 
18:0 3.43 3.79 1.98 4.57 4.39 
18:1 (c9) 3.89 21.64 26.63 10.58 20.39 
18:1 (c11) 0.32 0.84 0.62 1.37 2.66 
18:2 18.03 24.31 53.13 54.24 33.82 
19:0 0.16     
20:0 1.20 1.44 0.45 0.20 0.49 
18:3 34.19 8.0 1.61 9.05 7.22 
20:1 0.12  0.39   
20:2      
20:3  0.30    
22:0 2.10 1.92 0.19 0.44 0.45 
22:1 0.50 0.57  0.15  
24:0 1.24 2.26 0.24 0.29 0.69 
24:1 2.17 0.36    
Ether extract, % 
of DM 
3.64 2.56 4.58 3.85 5.80 





Table 3.3. Amount of fatty acid supplemented, g/d 
 
 Fatty acid 
Treatments 
S0 S200 S400 S600 
 8:0 0.5 7.5 14.4 21.3 
10:0 0.2 15.0 29.9 44.7 
12:0 2.9 21.5 40.1 58.8 
12:1  0.2 0.5 0.7 
14:0 6.6 68.5 130.3 192.2 
16:0 273.6 276.0 278.4 280.8 
16:1 0.7 0.4 0.2  
17:0 0.7 0.5 0.2  
18:0 23.4 15.8 8.2 0.5 
18:1 (c-9) 166.3 110.9 55.4  
18:2 30.8 20.5 10.3  
20:0 1.7 1.2 0.6  
18:3  0.6 0.4 0.2  
20:1 0.6 0.4 0.2  





Table 3.4. Least squares means for production responses to increasing short-and medium-chain fatty acids 
a–d Means within a row with different superscripts differ (P < 0.05). 
1 Probability of a significant effect of SMCFA or of a linear or quadratic effect of increasing amounts of dietary SMCFA 
2 Milk urea nitrogen 




 Treatments  P-value1 
Item S0 S200 S400 S600 SEM SMCFA Linear Quadratic 
DMI, kg/d 26.6  26.4  26.5  25.5  0.53 0.24 0.12 0.26 
NEL, Mcal/d 39.3 39.3 39.3 37.8 0.75 0.20 0.10 0.20 
Milk, kg/d 43.6 43.9 42.7 41.1 1.14 0.08 0.03 0.18 
3.5% FCM, kg/d 45.0 46.7 46.0 44.8 1.83 0.36 0.67 0.12 
3.5% FCM/DMI 1.70b 1.76a 1.73ab 1.75a 0.04 <0.01 0.03 0.16 
Milk fat, % 3.76 b 3.92 ab 4.01 a 4.10 a 0.16 <0.01 <0.01 0.34 
Milk fat, g/d 1614 1709 1694 1663 89.9 0.28 0.40 0.11 
Milk protein, % 3.10 ab 3.12 a 3.09 ab 3.06 b 0.05 0.03 0.01 0.07 
Milk protein, g/d 1351 ab 1373 a 1318 ab 1257 b 41.5 0.05 0.02 0.13 
MUN2, mg/dL 10.54a 10.16b 10.49a 10.02b 0.44 <0.01 <0.01 0.29 
SCC3. 1000's/mL 115b 118b 148a 129ab 2.3 <0.01 0.01 0.1 
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Table 3.5. Least squares means for fatty acid composition (%) of milk from cows in response to S0, S200, S400, and S600 
treatments 
 Treatments  P-value 
Fatty acid S0 S200 S400 S600 SEM Treatment Linear Quadratic 
                       g/100g FAME     
4:0 3.22 3.24 3.39 3.20 0.19 0.66 0.26 0.59 
6:0 2.07 2.07 2.15 2.06 0.12 0.74 0.30 0.84 
8:0 1.31 1.31 1.33 1.26 0.06 0.69 0.29 0.64 
10:0 3.20 3.21 3.12 2.98 0.14 0.42 0.38 0.16 
12:0 3.87 4.02 4.11 4.10 0.14 0.50 0.72 0.21 
14:0 11.10a 11.99 b 13.22 c 14.04 c 0.27 <0.01 0.18 <0.01 
14:1 1.65 a 1.74 ab 1.94 b 2.17 c 0.07 <0.01 0.01 <0.01 
15:0 1.16 1.11 1.19 1.19 0.08 0.61 0.82 0.24 
15:1 0.25 0.25 0.23 0.25 0.03 0.81 0.56 0.43 
16:0 34.80 b 35.80 ab 36.68 a 37.33 a 0.65 <0.01 0.66 <0.01 
16:1 (n9) 0.52 0.50 0.51 0.52 0.02 0.74 0.43 0.87 
16:1 (n7) 2.50 2.52 2.65 2.95 0.20 0.07 0.14 0.03 
17:0 0.45 0.43 0.43 0.42 0.01 0.17 0.84 0.08 
18:0 6.72 a 6.76 ab 6.19 ab 5.86 b 0.28 0.05 0.38 <0.01 
18:1 (c9) 19.16 a 18.14 a 16.37 b 15.18 b 0.48 <0.01 0.17 <0.01 
18:1 (t9) 1.40 1.22 1.67 1.38 0.18 0.71 0.29 0.81 
18:1 (c11) 0.32 a 0.30 ab 0.28 ab 0.26 b 0.01 0.05 0.72 0.01 
18:1 (t11) 0.68 0.63 0.65 0.64 0.05 0.65 0.99 0.71 
18:2 (t,t) 0.34 a 0.34 a 0.28 b 0.25 b 0.02 <0.01 0.28 <0.01 
18:2 (n6) 1.98 2.17 1.81 1.78 0.21 0.08 0.60 0.02 
18:3 (n3) 0.23 a 0.21 a 0.19 ab 0.18 b 0.01 <0.01 0.42 <0.01 
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Total 18 30.83 a 29.78 a 26.94 b 25.51 b 0.86 <0.01 0.24 <0.01 
19:0 0.12 0.14 0.12 0.13 0.02 0.85 0.93 0.67 
20:0 0.13 a 0.14 a 0.12 ab 0.09 b 0.01 0.02 0.04 0.01 
20:1(c8) 0.13 0.10 0.11 0.09 0.03 0.65 0.80 0.43 
20:1 (c11) 0.17 0.16 0.14 0.15 0.02 0.53 0.56 0.18 
21:0 0.15 a 0.13 ab 0.13 ab 0.11 b 0.01 0.01 0.38 0.02 
20:3 (n3) 0.14 0.14 0.13 0.11 0.01 0.40 0.49 0.13 
20:4 (n6) 0.19 a 0.17 ab 0.16 ab 0.13 b 0.02 0.02 0.32 0.01 
Total 20 0.76 a 0.71 ab 0.66 ab 0.58 b 0.05 <0.01 0.26 <0.01 
DNFA2 42.17c 43.75bc 45.65ab 46.26a 0.77 <0.01 0.92 <0.01 
MUFA3 26.78a 25.57ab 24.03b 23.57c 0.69 <0.01 0.94 <0.01 
PUFA4 2.74ab 2.88a 2.44ab 2.34b 0.23 0.01 0.44 <0.01 
SFA5 68.30b 70.37ab 72.17a 72.73a 0.95 <0.01 0.89 <0.01 
a–c Least squares means within a row with different superscripts differ (P < 0.05). 
1 Fatty acid methyl ester 
2 Denovo FA (DNFA) includes C4:0, C6:0, C8:0, C10:0, C12:0, C14:0 and half of C16 yield. 
3
 Mono-unsaturated FA 
4 Poly-unsaturated FA 




Table 3.6. Least squares means for yield (g/d) of fatty acids in milk from cows in response to S0, S200, S400, and S600 
treatments  
 Treatments  P-value 
Fatty acid S0 S200 S400 S600 SEM Treatment Linear Quadratic 
                                               g of FAME1 / day 
4:0 48.68 51.38 53.36 50.92 4.82 0.78 0.48 0.51 
6:0 31.32 33.03 33.89 32.35 3.13 0.86 0.52 0.67 
8:0 19.89 20.94 20.99 19.99 1.83 0.90 0.51 0.95 
10:0 48.25 51.11 49.10 47.33 4.03 0.87 0.59 0.66 
12:0 58.37 63.72 64.61 64.61 4.72 0.65 0.77 0.38 
14:0 167.08 b 188.46 ab 206.56 ab 219.85a 12.21 <0.01 0.70 <0.01 
14:1 24.75 c 27.44 bc 30.23 ab 33.19 a 1.72  <0.01 0.35 <0.01 
15:0 17.34 17.56 18.63 18.69 1.65 0.81 0.99 0.33 
15:1 3.75 3.92 3.46 3.81 0.47 0.74 0.52 0.52 
16:0 523.79 565.58 572.34 585.99 39.47 0.44 0.99 0.23 
16:1 (n9) 7.75 7.79 7.88 7.92 0.38 0.99 0.96 0.72 
16:1 (n7) 37.51 39.79 41.56 44.35 2.81 0.28 0.59 0.09 
17:0 6.68 6.75 6.61 6.56 0.49 0.97 0.89 0.67 
18:0 100.45 105.85 95.40 92.17 6.64 0.36 0.56 0.11 
18:1 (c9) 284.60 a 281.86 a 253.52 ab 235.65 b 11.70 <0.01 0.30 <0.01 
18:1 (t9) 20.74 19.09 18.26 19.00 1.62 0.64 0.54 0.36 
18:1 (c11) 4.73 4.64 4.36 4.30 0.42 0.67 0.95 0.23 
18:1 (t11) 10.11 9.83 10.24 9.71 0.78 0.92 0.63 0.99 
18:2 (t,t) 5.36 ab 5.66 a 4.69 ab 4.30 b 0.40 0.02 0.32 <0.01 
18:2 (n6) 32.09 36.36 30.26 29.23 3.92 0.08 0.42 0.03 
18:3 (n3) 3.67 a 3.57 a 3.17 ab 2.92 b 0.24 <0.01 0.32 <0.01 
Total 18 458.98 a 463.81 a 417.33 b 394.83 b 21.7 0.02 0.37 <0.01 
19:0 2.02 2.30 1.94 2.04 0.41 0.86 0.98 0.59 
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20:0 2.10 ab 2.32 a 2.03 ab 1.53 b 0.21 0.03 0.04 0.02 
20:1(c8) 2.04 1.75 1.81 1.57 0.42 0.83 0.79 0.57 
20:1 (c11) 2.71 2.68 2.46 2.53 0.32 0.86 0.82 0.40 
21:0 2.41 2.19 2.17 1.86 0.24 0.10 0.32 0.07 
20:3 (n3) 2.21 2.26 2.09 1.91 0.19 0.55 0.46 0.21 
20:4 (n6) 3.00 2.73 2.63 2.13 0.40 0.10 0.27 0.05 
Total 20 11.25 10.96 10.28 9.02 0.77 0.09 0.24 0.03 
DNFA 2 635.49 691.43 714.70 728.06 47.65 0.31 0.92 0.12 
MUFA3 398.37 398.50 373.48 361.76 17.13 0.25 0.61 0.05 
PUFA4 41.15ab 45.08a 38.00ab 35.98b 0.23 0.03 0.32 <0.01 
SFA5 1,028 1,111 1,127 1,144 73.98 0.47 0.89 0.24 
a–c Least squares means within a row with different superscripts differ (P < 0.05) 
1Fatty acid methyl ester 
2 Denovo FA includes C4:0, C6:0, C8:0, C10:0, C12:0, C14:0 and half of C16 yield. 
3
 Mono-unsaturated FA 
4 Poly-unsaturated FA 




Figure 3.1. Fatty acid composition of short- and medium-chain fatty acid mixture relative 































Figure 3.2. Transfer efficiency of individual short-and medium-chain fatty acids into 
















































Chapter 4: EXPERIMENT 2 
 
Milk fat responses to butterfat infusion during conjugated linoleic acid-induced 
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infusion of butterfat during CLA induced milk fat depression in lactating dairy cows.  J. 





During diet-induced milk fat depression (MFD), the short-and medium-chain fatty 
acids (SMCFA), which are synthesized denovo in the mammary gland, are reduced to a 
much greater extent than the long-chain fatty acids (LCFA) that originate from the 
circulation. Our hypothesis was that increased availability of SMCFA might rescue 
conjugated linoleic acid (CLA)-induced MFD in lactating dairy cows. To test that 
hypothesis, 4 ruminally fistulated lactating Holstein cows (128±23 DIM) were used in a 
4x4 latin square design with 3 wk experimental periods. Treatments were applied during 
the last 2 wk of each period and included 3X daily abomasal infusion of a total of :  1) 
230 g/d of LCFA (LCFA, blend of 59% cocoa butter, 36% olive oil and 5% palm oil); 2) 
420 g/d butterfat (BF); 3) 230 g/d LCFA with 27 g/d CLA (LC-CLA) containing 10 g/d 
of trans-10, cis-12 CLA; and 4) 420 g/d butterfat with 27 g/d CLA (BF-CLA).  Butterfat 
provided 50% of C16 and similar amounts of C-18 FA as found in LCFA such that the 
difference between the BF and LCFA treatments were 190g/d SMCFA.  No treatment 
effects were observed for DMI or milk yield. Milk fat content was signif cantly reduced 
by 41% and 32%, respectively, with LC-CLA and BF-CLA. Milk fat yield was 
significantly reduced by 41% and 38% with LC-CLA and BF-CLA respectively 
compared to their respective controls.  CLA infusion significantly reduced denovo 
synthesized FA (DNFA).  The concentration of DNFA was significantly reduced with 
CLA but DNFA tended to be greater with BF infusion. Infusion of CLA significantly 
reduced the expression of mammary lipogenic genes involved in denovo FA synthesis 
(ACC, FASN), FA uptake (LPL), FA desaturation (SCD) and triglyceride synthesis 
(AGPAT, DGAT). Protein abundance of the enzymes ACC and FASN that are involved in 
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DNFA synthesis were also significantly reduced. The increased availability of SMCFA 
increased LPL mRNA expression but no other effects were observed for lipogenic gene 
expression. The results suggest that nutritional manipulation by increasing the intestinal 




 Milk fat synthesis depends on two general sources of FA i.e. denovo synthesis of 
FA in mammary gland and transfer of preformed FA from blood triglycerides (TG). The 
short-and medium-chain FA (SMCFA, C4-C14) and half of C16 are synthesized denovo, 
whereas rest FA including 50% of C16 and other long-chain FA (LCFA) are derived 
from TG in the blood (Jensen, 2002).  
 Milk fat synthesis is highly responsive to nutritional manipulation and nutrition 
has been used as a practical tool to alter milk fat yield and FA composition (Sutton, 
1989). Certain dietary alterations including high-concentrate diets and diets high in 
polyunsaturated FA (PUFA) can induce a low milk fat syndrome, reducing milk fat 
percentage and yield up to 46% and is commonly termed as milk fat depression (MFD) 
(Piperova et al., 2000; Peterson et al., 2003). During MFD, mammary lipogenesis is 
inhibited by specific FA intermediates produced during rumen biohydrogenation 
(Bauman and Griinari, 2003). The relationship between tra s-10, cis-12 CLA and MFD 
is well established (Baumgard et al., 2000). The infusion of trans-10, cis-12 CLA  is 
accompanied with dramatic reduction of mRNA abundance of enzymes involved in 
denovo FA synthesis (acetyl-CoA carboxylase, ACC; fatty acid synthase, FASN), 
mammary uptake and intracellular transport of FA (lipoprotein lipase, LPL; fatty acyl 
binding protein, FABP), FA desaturation (stearoyl-CoA desaturase, SCD) and TG 
synthesis (glycerol-3-phosphate acyl transferase, GPAT; acylglycerol-3-phosphate acyl 
transferase, AGPAT) (Piperova et al., 2000; Peterson et al., 2003). The coordinated 
downregulation of mammary lipogenic enzymes during MFD suggests a major role f
transcription factors such as sterol regulatory element binding protein (SREBP-1) in 
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mammary lipogenesis (Harvatine and Bauman, 2006). During diet-induced MFD, the 
SMCFA, which are synthesized de novo in the mammary gland, are reduced to a much 
greater extent than the long-chain fatty acids (LCFA), which originate from circulating 
blood TG originating from the diet and tissue-mobilized TG (Chouinard et al., 1999; 
Baumgard et al., 2002). 
 The SMCFA are essential for formation of milk TG (Moore and Steele, 1968) and 
for maintaining the fluidity of milk fat (Barbano and Sherbon, 1980). Recently, the 
importance of SMCFA during milk fat synthesis was underscored when post-ruminal 
infusion of butterfat, used as a source of SMCFA, increased milk fat synthesis in lactating 
dairy cows (Kadegowda et al., 2008). This suggests that the mammary gland is 
responsive to SMCFA during normal milk fat synthesis. We hypothesized that the 
responsiveness to SMCFA would be greater when denovo synthesis of these FA is 
inhibited. The objective of the present study was to determine whether CLA-induced 
MFD can be reversed/ prevented by SMCFA availability. 
MATERIALS AND METHODS 
Animals, Experiment Design, Treatment, and Sampling.  
All procedures for this experiment were conducted under a protocol approved by 
the University of Maryland Institutional Animal Care and Use Committee. Four 
ruminally fistulated multiparous Holstein dairy cows in mid lactation (128 ± 23 DIM) 
were used in 4x4 Latin square design balanced for carryover effects. Treatments were 
abomasal infusion of the following: 1) 230 g/d of long-chain FA (LCFA); 2) 420 g/d 
butterfat (BF); 3) 230 g/d LCFA with 27 g/d CLA (LC-CLA) containing 10 g/d of trans-
10, cis-12 CLA; and 4) 420 g/d butterfat with 27 g/d CLA (BF-CLA).  
 
In the LCFA treatment, only 50% of the palmitic acid found in the butterfat was 
included, because it has been estimated that 
synthesized de- novo (Palmquist and Jenkins, 1980)
59% cocoa butter (Bloomer Chocolate Company, Chicago, IL), 36% olive oil (Filippo 
Berio, Hackensack, NJ), and
D.C.). In the BF treatment, butter oil was prepared from commercially available unsalted 
butter (Kirkland Signature, Costco Wholesale Corporation, Seattle, WA
and separated from the protei
from Clarinol® (Lipid Nutrition, Maywood, NJ). Amounts of postruminally infused 
individual FA in the LCFA mixture and butterfat are shown in
composition of the fat supplements is p
Experimental periods were 3 wk. The first week of each period was without fat 
infusion to reduce carryover effects. This was followed by 2 wk of abomasal infusion. Fat 
supplements were infused via tygon tubing (0.48
Bridgeport, NJ) that passed through the ruminal cannula, the rumen, the omasum, and 
into the abomasum, where the line was maintained using a 10
flange. The fat mixtures were liquified at 37°C in a warming oven and 
infusion. The amount of each FA mixture was divided into equal portions and manually 
infused 3 times per day (140
1400, and 1900h). Actual amounts of infused fat were recorded daily
location of the infusion line inside the cow were che ked on alternate days.
approximately 50% of palmitic acid is 
. The LCFA mixture was a blend of 
 5% palm oil (Malaysian Palm Oil Board, Washington
) melted at 37°C 
n coagulate by filtration. The CLA mixture was prepared 
 Figure 4.1.  The FA 
resented in Table 4.2. 
-cm i.d, 0.64-cm o.d; VWR Scientific, 
-cm circular plastisol 
mixed well before 
g of butterfat, 76.6 g of LCFA, and 9g of CLA at 0800, 






Cows were housed in individual tie stalls equipped with rubber mats and bedded 
with wood shavings. Cows were fed a basal diet containing 50% forage and 50% 
concentrate (DM basis) to meet NRC (2001) nutrient specifications for a 600-kg cow 
producing 45 kg of milk containing 3.7% milk fat and 3.1% milk protein. Ingredient and 
chemical composition of the basal diet are given in Table 4.1. Diets were fed as TMR 
once daily at 0800 h. Forage and ingredient DM were measured weekly, and the TMR 
was adjusted accordingly to maintain a constant forage-to-concentrate raio on  DM 
basis. Amounts of feed offered and refused were recorded once daily. Cows were milk d 
twice daily at 0700 and 1700 h, and milk production was recorded electronically at each 
milking. Samples for milk composition and FA analysis were collected from the last 6 
consecutive milkings during wk 3 of each experimental period. Milk fat, protein, and 
somatic cell counts (SCC) were determined by infrared analysis (Foss Milk-O-Scan, Foss 
Food Technology Corp., Eden Prairie, MN) on fresh samples from individual milkings. A 
subset of samples from each milking was composited and frozen at -20oC for subsequent 
FA analysis. Transfer efficiency of each FA was calculated as the increased output in 
milk divided by the infused FA.  
FA Composition Analysis 
 Milk FA composition was analyzed from pooled milk samples from last 6 
consecutive milkings of wk 3. The FA methyl esters (FAME) were prepared by mild 
transesterification with 1.4 mol/L of H2SO4
 in methanol (Christie, 1982). Separations 
were achieved using an Agilent 6890N gas chromatograph (Agilent Technologies., 
Wilmington, DE) equipped with a flame ionization detector. Hydrogen was used as 
carrier gas at 1 mL/min constant flow with a linear velocity of 30 cm/s. Air flow was 
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maintained at 400 mL/min. Nitrogen was used as make up gas a flow rate of 33 mL/min. 
The oven was maintained at 169oC isothermal temperature, the injection port at 250oC, 
and the detector at 250oC. The split ratio was set to 1:100 and the typical injection 
volume was 1 uL.  
The SMCFA were analyzed as fatty acid butyl esters (FABE), which were 
mathematically converted to FAME and normalized to the FAME chromatogram (Gander 
et al., 1962). The original FABE procedure was modified as follows. Milk samples were 
heated in screw-capped test tubes at 80oC for 1 h in the presence of 1.4 N H2SO4
 in 
butanol, followed by extracting with hexane in the presence of saturated KCl and distilled 
water. Samples were then centrifuged at 500 x g for 5 min at room temperature. Aliquot 
of the upper hexane layer was injected directly into a Hewlett-Packard 5880 gas-liquid 
chromatograph equipped with a split injector, a flame ionization detector and a 25 m x 0.2 
mm i.d. fused silica capillary column coated with HP1 (Hewlett Packard, Avondale, PA). 
Helium was used as the carrier gas at a flow rate of 2 mL/min with a split ratio of 45:1. 
Injector temperature and detector temperature were set at 250°C while column 
temperature started at 130°C. Ramp was set at 6oC/min to 290oC, followed by 4oC/min to 
260oC and finally holding at 260oC for 20 min. Standard mixtures, including GLC-60 
(Nu-check Prep, Inc., Elysian, MN), were converted to FABE to aid in the identification 
and quantification of FA. 
Mammary Biopsy 
 Mammary biopsies were performed on d 21 of each experimental period. Biopsies 
were taken from either on the left or right rear gland. The biopsy site was carefully 
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selected to avoid larger subcutaneous blood vessels. Preparation of the site involved 
shaving and washing with dilute betadine (Purdue Frederick, Stamford, CT) solution 
followed by sanitizing with ethyl alcohol (70%). Cows were given intravenous xylazine 
before anesthetizing the biopsy site by subcutaneous injection of lidocaine hydrochloride 
(line block). An incision was made (~0.5-1.0 cm) on the outside of the quarter using a 
scalpel blade (size 22). A Bard® Magnum®  core biopsy instrument (Bard Peripheral 
Vascular, Inc., Tempe, AZ) with a Bard® Magnum® core tissue biopsy needle (MN1210, 
12G × 10 cm) was used to biopsy mammary tissue (30-50 mg tissue /biopsy). Tissue 
samples were snap frozen in liquid N2 and stored at −80°C.  
RNA Isolation and Quantitative Real-Time Reverse-Transcription PCR 
Frozen biopsy tissues were weighed (~30 mg) and immediately subjected to RNA 
extraction using Qiagen RNeasy mini kit with on-column DNAse digestion (Qiagen, 
Valencia, CA). The RNA concentration and quality was measured using a NanoDrop 
ND-1000 spectrophotometer (Wilmington, DE). The purity of RNA (A260/ 280) for all 
samples was above 1.9.  The RNA integrity was assessed by electrophoretic analysis of 
28S and 18S rRNA subunits using agarose gel electrophoresis.   
A portion of the extracted RNA was diluted to 1µg/µL using DNase-RNase free 
water prior to reverse transcription. The cDNA was synthesized from 1µg RNA using the 
iScript cDNA Synthesis Kit (Bio-Rad Laboratories Inc., Hercules, CA) as per the 
manufacturer’s instructions. A negative control to check for genomic DNA 
contamination was prepared by pooling RNA from each sample, and using 1 µg in a 
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reaction without reverse transcriptase. All first-strand cDNA reactions were diluted 5-
fold prior to use in PCR.  
Primer sequences utilized in these experiments are detailed in Table 4.3. The 
mRNA levels were quantified using the MyiQ Single-Color Real-Time PCR Detection 
System (Bio-Rad) and the 2X Quantitect SYBR Green PCR Master Mix (Bio-Rad). 
Cycles were performed as follows: denaturation at 95oC for 3 min to activate the 
polymerase, followed by 40 cycles of 95oC for 15 s, 60oC for 30 s, and 72oC for 30 s. The 
presence of a single PCR product and the absence of primer-dimers were verified by the 
melt curve analysis using incremental temperatures to 95°C for 15 s plus 65°C for 15 s. 
Data were normalized to the housekeeping gene Ubiquitously expressed transcript (UXT) 
after comparing the expression of UXT, Mitochondrial ribosomal protein L39 (MRPL39) 
and Eukaryotic translation initiation factor 3, subunit K (EIF3K) (Kadegowda et al., 
2009). The stability of housekeeping genes were tested by Normfinder software 
(Molecular Diagnostics Lab, Aarhus, DK). Data were transformed using equation 2-∆∆Ct 
(Livak and Schmittgen, 2001), where Ct represents the fractional cycle number when the 
amount of amplified product reaches a threshold for fluorescence. The normalized data 
were transformed to obtain a perfect mean of 1.0 for the LCFA treatment, leaving the 
proportional difference between the biological replicates. The same proportional change 
was calculated in all the treatments to obtain a fold change relative to LCFA treatment. 
Protein Isolation and Western Blotting 
 Protein isolation and western blotting procedures were adapted from (Rudolph et 
al., 2010). Briefly, mammary lysis buffer [50 mM Tris (pH 7.4), 150 mM NaCl, 2.0 mM 
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EDTA, 50 mM NaF, 5.0 mM sodium vanadate, 1% Triton X-100, 1% deoxycholate, and 
0.1% SDS] to which 0.57 mM phenylmethylsulfonyl fluoride (PMSF), 20 µL/mL EDTA-
free protease inhibitor cocktail (Roche, Applied Science, Indianapolis, IN), and 1.0 mM 
DTT were added to extract proteins from the mammary samples. Samples were 
homogenized using a Brinkman homogenizer, and lysate was centrifuged at 13,000 g for 
20 min at 4°C. Protein concentrations in the supernatant were determined using 
bicinchoninic acid (Pierce, Rockford, IL). Proteins were resolved using 8% SDS-
polyacrylamide gels(Laemmli, 1970). Resolved proteins were transferred to 
nitrocellulose membrane (Biorad laboratories, Hercules, CA).  Antibodies directed 
against acetyl-CoA carboxylase-1 (Polyclonal antibodies raised in rabbit; Catalogue # 
3662S) and fatty acid synthase (Polyclonal antibodies raised in rabbit; Catalogue # 
3180S) and secondary antibodies (Anti-rabbit IgG, HRP linked antibody; Catalogue # 
7074S) were obtained from Cell Signaling Technology (www.cellsignal.com, Danvers, 
MA).  
Statistical Analysis 
  Milk production, milk components, gene expression, protein expression and FA 
composition data were analyzed as a 2x2 factorial arrangement of treatments in 4x4 Latin 
square design using the MIXED procedure in SAS (Version 9.2, SAS Institute, Cary, 
NC). The statistical model included the effect of cow and experimental period, type of fat 
(BF or LCFA), CLA (with or without CLA infusion) and fat x CLA interaction.  One cow 
was diagnosed with displaced abomasum and surgically repaired during wk 2 of period 1. 
To allow for recovery from surgery, period 1 data from this cow was not included in the
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analysis. A probability of P ≤ 0.05 was considered statistically significant. The results are 
presented as least squares means.  
RESULTS 
The FA profile of the infused FA mixture is presented in Table 4.2. The CLA 
supplement was a mix of 42% cis-9, trans-11 and 45% trans-10, cis-12 CLA. The LCFA 
mixture was formulated to provide 50% of palmitic acid and the remainder of LCFA 
equivalent to BF treatment.  
Intake and milk production responses are presented in Table 4.4. No treatment or 
interaction effects were observed for DMI and milk yield. However, CLA infusion 
reduced 3.5% FCM by 25% with BF and LCFA (P < 0.01). The feed conversion 
efficiency (FCM/DMI) was reduced with CLA (P < 0.01) while no effects were observed 
due to type of infused fat (P = 0.46). Milk fat percentage was reduced by 32 and 41% (P 
< 0.01) and milk fat yield was reduced by 38 and 41% (P < 0.01) with BF-CLA and LC-
CLA respectively. There were no treatment effects on milk protein yieldand content. 
Concentrations and yields of individual milk FA are in Table 4.5 and 4.6, 
respectively. Abomasal infusion of CLA altered milk FA composition as it shifed 
towards higher proportions of LCFA (> 16 carbons) due to a reduction in the secretion of 
DNFA. Conjugated linoleic acid infusion reduced the DNFA content by 11 and 15% (P < 
0.01) and yield by 44% and 50% (P < 0.01) with BF-CLA and LC-CLA, respectively. 
The concentration and yield of all SMCFA including C6, C8, C10 and C12, along with 
C16 were reduced (P < 0.01) with CLA infusion, with the exception of C14. The milk fat 
content of C14 remained constant while the yield was reduced with CLA infusion (P < 
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0.01). While milk fat content of C18:0, total C18:1 and total C18:2 were increased with 
CLA (P < 0.01) infusion, the yield of the respective FA was reduced (P < 0.01). 
Concentrations and yield of individual 18:1 and 18:2 FA isomers are in Table 4.7 and 4.8, 
respectively. Total trans-18:1 including trans-5/7, trans-8/9, trans-11, trans-13/14, and 
trans-16 increased with CLA infusion (P < 0.01). The concentration of total 18:1-cis (P = 
0.09), cis-9 (P = 0.10) and cis-15 (P = 0.10) tended to increase while cis-13 (P = 0.01) 
and cis-14 18:1 (P = 0.04) were increased with CLA infusion. Total CLA concentration 
was increased by 166 and 116% and CLA yields were increased by 56 and 43% with LC-
CLA and BF-CLA, respectively (P < 0.01).  The concentrations of individual CLA 
isomers including cis-9, trans-11(P < 0.01), trans-10, cis-12 (P < 0.01), trans-9, cis-11(P 
< 0.01) and trans-11, trans-13 (P = 0.01) were also increased. Yield of cis-9, trans-11 
CLA tended to increase (P = 0.06) by 29 and 27% with LC-CLA and BF-CLA 
treatments, respectively, (P < 0.01) with a transfer efficiency of ~17%. The yield of 
trans-10, cis-12 was increased (P < 0.01) with CLA infusion with a transfer efficiency of 
19 and 20% with LC-CLA and BF-CLA treatments, respectively. 
The milk FA profile in response to BF or LCFA infusion without CLA was not 
markedly altered. Concentrations of SMCFA including C6, C8, C10, and C12 remained 
constant while C14:0, 14:1 cis-9, and 16:1 cis-9 increased (P < 0.01) with BF as 
compared to LCFA infusion.  The total DNFA concentration tended to be higher with BF 
infusion (P = 0.09). However, no effects were observed on DNFA yield (P = 0.43). 
Similarly, the content and yield of MUFA and PUFA were similar irrespectiv  of type of 
fat infused (P = 0.72; P = 0.67 respectively). The content of 18:0 was greater (P < 0.01) 
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while total 18:1 tended to be geater with LCFA infusion while the yield of the respective 
FA remained constant between BF and LCFA treatments.  
Abomasal infusion of CLA altered mammary lipogenic enzyme and gene 
expression. The mRNA abundance of ACC and FASN (Figure 4.2), AGPAT, 
diacylglycerol acyl transferase (DGAT) (Figure 4.3), LPL (Figure 4.4), and SREBP-1 
(Figure 4.5) was reduced (P < 0.01) with CLA infusion, with the exception of stearoyl-
CoA desaturase (SCD) (Figure 4.4) and peroxisosome proliferator activated receptor-γ 
(PPAR-γ) (Figure 4.5). The mRNA abundance of LPL was increased (P < 0.01) and that 
of SREBP cleavage activating protein (SCAP) (Figure 4.6) tended (P < 0.10) to increase 
with BF infusion compared to LCFA. The interaction between type of fat and CLA was 
significant for SCD (P < 0.05). The mRNA expression of INSIG was reduced with CLA 
while no effects were observed with type of fat infused (Figure 4.6). Similarly, CLA 
infusion reduced lipogenic protein expression in mammary gland. The expression of 
ACC and FASN was reduced with CLA (P < 0.01). However, the type of fat infused had 
no effect on protein expression. Similar response was observed with Fat x CLA 
interaction.   
DISCUSSION 
As SMCFA are reduced to the greater extent relative to LCFA during MFD, our 
hypothesis was that post-ruminal infusion of SMCFA could alleviate at least a portion f 
CLA-induced MFD. Butterfat, used as a source of SMCFA provided an additional 190 
g/d SMCFA. Thus, compared to LCFA the responses observed by comparing BF and 
LCFA treatments could be attributed to SMCFA. The CLA supplement in the present 
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study contained two major CLA isomers, trans-10, cis-12 CLA and cis-9, trans-11 CLA. 
However, previous studies have shown that cis-9, trans-11 CLA isomer had no effect on 
milk fat synthesis in dairy cows (Baumgard et al., 2000; Baumgard et al., 2002; Loor and 
Herbein, 2003). Hence, it is assumed that milk fat responses with CLA supplement in the 
present study are due to trans-10, cis-12 CLA isomer.  
Conjugated linoleic acid induced MFD in the present study further verified the 
role of trans-10, cis-12 CLA as a potent inhibitor of milk fat synthesis (Chouinard et al., 
1999; Baumgard et al., 2000). Milk FA profile during MFD is characterized by reduced 
secretion of FA originating from denovo synthesis and reduced FA uptake from 
circulation with effects more pronounced on DNFA (Bauman and Griinari, 2003). The 
changes in milk FA profile appeared to be mainly due to reduced mammary lipogenesis 
which further is regulated by SREBP-1 gene expression. The CLA-induced responses on 
milk FA profile and mammary lipogenic gene expression in the present study are 
consistent with previous studies using either pure trans-10, cis-12 CLA isomer 
(Baumgard et al., 2002; Gervais et al., 2009) or during diet-induced MFD (Opstvedt et 
al., 1967; Piperova et al., 2000; Peterson et al., 2003). However, to our knowledge, this is 
the first study measuring ACC and FASN protein expression during CLA-induced MFD. 
The protein expression of ACC and FASN reflected the changes in mRNA expression of 
the respective enzyme. These findings further support the assumption that mammary 
lipogenesis is regulated at the level of mRNA expression (Rudolph et al., 2007). In 
contrast, increased availability of SMCFA with BF infusion had no effects on milk fat 
responses unlike previous study where abomasal infusion of BF increased milk fat yield 
(Kadegowda et al., 2008). The differences in the responses were more apparent when the 
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transfer efficiency of individual SMCFA was considered. The DNFA including 
individual SMCFA were transferred with the greater efficiency in the previous study 
(Kadegowda et al., 2008). The increased availability of SMCFA along with greater 
mRNA abundance of both ACC and FASN might explain greater milk fat responses with 
BF infusion (Kadegowda, 2008). It is difficult to reconcile the differences between both 
studies. However, the cows used in the present study had higher average milk production 
(48 vs. 32 kg/d) that might have affected the milk fat responses. The higher energy 
requirements for lactation might have reduced the transfer efficiency of SMCFA by 
increasing its extra-mammary utilization. Short-chain FA can be absorbed directly from 
the digestive tract into the portal vein and can be preferentially oxidized in liver as energy 
substrates (Souza and Williamson, 1993).  
The mRNA expression of LPL was reduced in cows receiving trans-10, cis-12 
CLA (Baumgard et al., 2002; Harvatine and Bauman, 2006; Gervais et al., 2009). 
Consistent with the previous findings, the mRNA abundance of LPL was reduced with 
CLA infusion in the present study. Lipoprotein lipase plays an important role in 
hydrolysis of plasma TG and is important for delivery of dietary FA to the mammary 
gland (Fielding and Frayn, 1998). The CLA-induced downregulation of LPL further 
suggests reduced uptake of blood TG. However, greater substrate availability with BF 
infusion increased LPL expression further increasing the availability of LCFA for their 
utilization by mammary gland (Annison et al., 1968). 
The improved milk fat responses with BF infusion was previously (Kadegowda, 
2008) attributed to the increased expression of LPL along with enzymes involved in TG 
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synthesis; AGPAT and DGAT. However, the expression of DGAT was not affected in the 
present study.  Diacylglycerol acyl trasferase catalyzes the committed and final step of 
TG synthesis determining the flux of available substrates into TG (Yen et al., 2008). This 
might explain the lack of milk fat response with BF infusion despite increased substrate 
availability. 
Stearoyl-CoA desaturase-1 regulates the availability of 18:1c9 by introducing a 
cis-9 double bond on the saturated chain of C18 (Cook et al., 1976). However, its 
specificity extends to other MCFA or LCFA such as C14 and C16 (Ntambi et al., 2004).
The desaturase index measured as product: substrate ratio has been used as indirect 
measure for SCD activity (Table 4.9). Trans-10, cis-12 CLA reduced desaturase index in 
some experiments (Baumgard et al., 2002) while no effects were observed in others 
(Gervais et al., 2009). Similarly, trans-10, cis-12 CLA can reduce mRNA expression by 
downregulating the transcriptional enhancer element of the SCD-1 gene promoter 
(Keating et al., 2006). However, the increased availability of SMCFA had no effect on 
either desaturase index or mRNA expression (Kadegowda et al., 2008). In the present
study, both CLA and fat source had no effect on desaturase index reflecting the lack of 
change in SCD-1 mRNA expression due to respective treatment. For unknown reasons, 
there was a FAT x CLA interaction for SCD-1 gene expression. However, the effects 
were not reflected on desaturase index. The lack of correlation between desaturas index 
and mRNA expression has been observed previously in bovine mammary gland (Bionaz 
and Loor, 2008) and could be attributed to posttranslational modifications, and factors 




Although the molecular mechanisms regulating milk fat synthesis are not well 
established, the coordinated down-regulation of mammary lipogenesis suggests the 
involvement of transcription regulation (Peterson et al., 2004; Harvatine and Bauman, 
2006). The role of SREBP-1 has been suggested as a global regulator of mammary lipid 
metabolism (Rudolph et al., 2007) both invitro in mammary epithelial cells (Peterson et 
al., 2004) and in lactating dairy cows (Harvatine and Bauman, 2006). The transcription 
factor SREBP-1 is synthesized as precursor protein associated with SCAP and is anchored 
to the endoplasmic reticulum with INSIG-1 protein. Upon activation, the SREBP 
precursor undergoes a sequential two step cleavage process and the mature protein is
translocated to the nucleus where it binds the target genes on sterol response elements 
(Wang et al., 1994; Sakai et al., 1998). Trans-10, cis-12 CLA downregulates the nuclear 
abundance of SREBP-1 by inhibiting proteolytic activation process of SREBP-1 protein 
or by inhibiting SREBP-1 gene transcription (Bernard et al., 2008). The mRNA 
abundance of its active nuclear fragment was decreased in response to trans-10, cis-12 
CLA in dairy cows (Harvatine and Bauman, 2006; Gervais et al., 2009), mice 
(Kadegowda et al., 2010) and bovine mammary epithelial cells (Peterson et al., 2004). 
The mRNA expression of SCAP and INSIG-1 were reduced in response to trans-10, cis-
12 CLA, suggesting post-transcriptional secondary regulation of SREBP-1 (Harvatine and 
Bauman, 2006). The CLA effects in the present study agree with the previous findings. 
However, increased availability of SMCFA had no effects on SREBP-1 expression 
contrary to what was observed earlier (Kadegowda, 2008).  
The PPAR-γ is an important member of the nuclear receptor super family of 
transcription factors. Bionaz and Loor (2008) suggested that PPAR- γ could be the main 
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transcription factor controlling milk fat synthesis by serving as a regulator for SREBP 
activity. Kadegowda et al. (2009) also showed marked upregulation of mammary 
lipogenic gene expression with Rosiglitazone, PPAR-γ agonist, in bovine mammary 
epithelial cells. However, the mRNA expression of PPAR-γ was not altered in the present 
study which agrees with the hypothesis that SREBP-1as the major regulator of mammary 
lipogenesis (Harvatine and Bauman, 2006).  
CONCLUSION 
While CLA reduced mammary lipogenesis, the increased availability of SMCFA 
failed to rescue CLA-induced MFD. The milk fat responses with SMCFA weresmall and 
non-significant with no effects observed on either mRNA or protein expression of 
lipogenic enzymes. The results suggest that nutritional manipulation with intestinal 
SMCFA was insufficient to rescue CLA-induced MFD. This suggests that CLA-induced 
MFD is caused by more than just an insufficient supply of SMCFA, typically provided by 
denovo FA synthesis in the mammary gland.   
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Table 4.1. Ingredient and chemical composition of the basal diet 
Item DM % 
Ingredient  
Corn silage 50.02 
Corn grain, Ground 26.01 
Soybean meal 20.21 
Corn gluten meal (60%) 0.45 
Limestone 0.62 
Calcium Phosphate 0.43 
Magnesium oxide 0.16 
Sodium bicarbonate 0.57 
Dynamate 0.13 
Salt 








CP, % 16.69 
RUP, %1 43.02 
ADF, % 16.98 









1Trace mineral and vitamin mix combined which provided an additional; 0.76 mg/kg Co, 
10 mg/kg Cu, 5.5 mg/kg Fe, 0.64mg/kg I, 37 mg/kg Zn, .33 mg/kg Se, 3,526 IU/kg 
vitamin A, 1175 IU/kg vitamin D, and 22 IU/kg vitamin E to the diet DM.  
2Calculated value based the estimated TDN from feed analysis at 3X maintenance int ke 














Table 4.2. Fatty acid composition of fat supplements infused in lactating dairy cows 
CLA Butterfat Palm oil Olive oil 
Cocoa 
Butter LCFA 





12:0 3.39 0.25 0.01 
13:0 0.16 
14:0 0.03 9.87 1.06 0.03 0.11 0.13 
15:0 1.48 0.05 0.03 0.02 
14:1  0.73 
16:0 0.18 27.46 41.15 13.82 25.25 22.06 
16:1  0.07 1.23 0.16 1.24 0.24 0.60 
17:0 1.14 0.10 0.08 0.23 0.17 
18:0 0.07 11.85 4.16 2.65 36.40 22.59 
17:1    0.19 0.03 0.12 0.04 
18:1 cis-9 5.26 21.12 40.82 69.12 32.83 46.41 
18:1 cis-11 0.37 0.53 0.75 2.78 0.34 1.24 
18:1 cis-12 0.51 0.00 
18:1 cis-13 0.11 0.06 0.01 
18:1 cis-14 0.05 
18:1 trans total   3.52 
18:2 trans-11,cis-15 0.14 0.07 0.19 0.03 0.02 
18:2 cis-9, cis-12 0.79 2.98 10.26 8.61 2.91 5.26 
18:3  0.34 0.18 0.42 0.17 0.26 
20:0 0.15 0.16 0.42 0.49 1.15 0.81 
20:1 cis-9 0.10 0.01 0.00 
20:1 cis-11 0.04 0.15 0.30 0.05 0.15 
20:2 1.18 
22:0 0.04 0.08 0.16 0.21 0.19 
18:2 trans-7,cis-9 0.04 
18:2, cis-9,trans-11 42.55 0.47 
18:2, cis-10,trans-12 0.89 
18:2, trans-9,cis-11 0.89 
18:2, cis-11,trans-13 0.73 
18:2, trans-10,cis-12 45.56 
C20:3 0.11 
C20:4 0.16 
1 Fatty acid methyl esters 
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Table 4.3.  Features of primers used for qPCR analysis 
Gene Accession #  Primers (5’-3’)1 bp2 Reference 
ACACA AJ132890 F CATCTTGTCCGAAACGTCGAT 102 Bionaz and Loor, 2008a 
    R CCCTTCGAACATACACCTCCA   
AGPAT6 DY208485 F AAGCAAGTTGCCCATCCTCA 101 Bionaz and Loor, 2008b 
  R AAACTGTGGCTCCAATTTCGA   
DGAT1 NM_174693 F CCACTGGGACCTGAGGTGTC 101 Bionaz and Loor, 2008a 
  R GCATCACCACACACCAATTCA   
FASN CR552737 F ACCTCGTGAAGGCTGTGACTCA 92 Bionaz and Loor, 2008a 
  R TGAGTCGAGGCCAAGGTCTGAA   
INSIG1 XM_614207 F AAAGTTAGCAGTCGCGTCGTC 120 Bionaz and Loor, 2008a 
  R TTGTGTGGCTCTCCAAGGTGA   
SCD-1 AY241933 F TCCTGTTGTTGTGCTTCATCC 101 Bionaz and Loor, 2008a 
  R GGCATAACGGAATAAGGTGGC   
LPL BC118091 F ACACAGCTGAGGACACTTGCC 101 Bionaz and Loor, 2008a 
  R GCCATGGATCACCACAAAGG   
PPAR-γ NM_181024 F CCAAATATCGGTGGGAGTCG 101 Bionaz and Loor, 2008a 
  R ACAGCGAAGGGCTCACTCTC   
SCAP DV935188   F CCATGTGCACTTCAAGGAGGA 108 Harvatine and Bauman, 2006 
  R ATGTCGATCTTGCGTGTGGAG   
SREBF1 DV921555 F CCAGCTGACAGCTCCATTGA 67 Loor et al., 2005 
  R TGCGCGCCACAAGGA   
UXT NM_001037471 F CAGCTGGCCAAATACCTTCAA 125 Kadegowda et al., 2009 
  R GTGTCTGGGACCACTGTGTCAA   
MRPL39 NM017446 F AGGTTCTCTTTTGTTGGCATCC 101 Kadegowda et al., 2009 
  R TTGGTCAGAGCCCCAGAAGT   
EIF3K NM_001034489 F CCAGGCCCACCAAGAAGAA 125 Kadegowda et al., 2009 
  R TTATACCTTCCAGGAGGTCCATGT   
1 Primer direction (F – forward; R – reverse)  
2 Amplicon size in base pairs (bp) 
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Table 4.4. Production responses from cows abomasally infused with long-chain FA (LCFA), LCFA with conjugated linoleic 
acid (LC-CLA), butterfat (BF) and BF with CLA (BF-CLA) 





 Treatments  P-value 
Item LCFA LC-CLA BF BF-CLA SEM Fat CLA Fat x 
CLA 
DMI, kg/d 25.4 22.6 24.9 24.0 1.15 0.66 0.12 0.41 
Milk, kg/d 47.9 46.9 49.2 46.1 5.77 0.91 0.21 0.49 
3.5% FCM, kg/d 46.7 35.5 47.9 35.9 4.97 0.54 <0.01 0.13 
3.5% FCM/DMI 1.84 1.69 1.93 1.48 0.23 0.46 <0.01 0.09 
Milk fat, % 3.36 1.99 3.37 2.30 0.19 0.41 <0.01 0.46 
Milk fat, g/d 1,600 937 1,640 1,013 163.91 0.50 <0.01 0.83 
Milk protein, % 2.93 2.97 2.98 3.05 0.06 0.33 0.40 0.87 
Milk protein, g/d 1,410 1,394 1,471 1,388 180.03 0.59 0.36 0.53 
MUN, mg/dL 14.3 12.0 12.5 11.9 1.31 0.40 0.21 0.46 
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Table 4.5. Least squares means for fatty acid composition of milk from cows infused with long-chain FA (LCFA), LCFA with 
conjugated linoleic acid (LC-CLA), butterfat (BF) and BF with CLA (BF-CLA) 
 Treatments  P-values1 
Fatty acid LCFA LC- CLA BF BF- CLA SEM Fat CLA Fat x 
CLA 
                                                        g/100 g of FAME2 
4:0 3.59 3.44 3.28 3.15 0.58 0.52 0.12 0.98 
6:0 2.12 1.47 1.91 1.43 0.19 0.35 <0.01 0.52 
8:0 1.29 0.91 1.18 0.87 0.10 0.33 <0.01 0.66 
10:0 2.96 2.08 2.86 1.96 0.25 0.42 <0.01 0.95 
12:0 3.52 2.72 3.73 2.78 0.28 0.35 0.01 0.60 
13:0 0.22 0.15 0.28 0.17 0.03 0.08 <0.01 0.40 
14:0 11.09 10.78 12.19 11.51 0.38 <0.01 0.09 0.41 
14:1(c9) 1.01 1.09 1.33 1.25 0.15 0.01 0.98 0.25 
15:0 1.06 0.91 1.39 1.01 0.17 0.11 0.06 0.38 
16:0 30.33 27.62 31.18 28.97 0.75 0.13 0.01 0.70 
16:1 (c9) 1.51 1.56 1.82 1.76 0.19 <0.01 0.96 0.41 
16:1 (c11) 0.04 0.07 0.06 0.09 0.01 0.01 <0.01 0.54 
17:0 0.47 0.48 0.52 0.48 0.04 0.09 0.36 0.18 
18:0 7.76 9.23 6.75 8.68 0.71 <0.01 <0.01 0.18 
18:1 24.38 27.02 22.39 25.28 1.51 0.07 0.02 0.89 
18:2 3.85 5.26 3.76 4.78 0.41 0.47 0.02 0.62 
18:3 (c9,c12,c15) 0.24 0.26 0.25 0.26 0.02 0.89 0.52 0.79 
20:0 0.14 0.15 0.12 0.15 0.00 0.10 0.01 0.34 
20:1 (c9) 0.09 0.09 0.09 0.09 0.00 0.69 0.22 0.83 
22:0 0.02 0.02 0.01 0.02 0.00 0.05 0.49 0.20 
22:4 0.04 0.03 0.04 0.03 0.00 0.89 0.04 0.66 
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22:5 0.05 0.04 0.05 0.04 0.00 0.91 <0.01 0.55 
Other 4.18 4.56 4.82 4.79 0.17 0.02 0.22 0.17 
DNFA3 42.57 36.06 43.27 38.64 1.52 0.09 <0.01 0.28 
MUFA4 27.69 30.63 26.51 29.39 1.59 0.19 0.01 0.97 
PUFA5 4.34 5.78 4.26 5.33 0.44 0.54 0.02 0.65 
SFA6 66.27 61.62 67.18 63.29 2.15 0.32 0.01 0.76 
1 Probability that the FAT, CLA or interaction effects were not different from zero 
2 Fatty acid methyl esters 
3 Denovo synthesized fatty acids 
4 Monounsaturated fatty acids 
5 Polyunsaturated fatty acids 























Table 4.6. Least squares means for fatty acid yield of milk from cows abomasally infused with long-chain FA (LCFA), LCFA 
with conjugated linoleic acid (LC-CLA), butterfat (BF) and BF with CLA (BF-CLA) 
 Treatments  P-values1 
Fatty acid LCFA LC- CLA BF BF- CLA SEM Fat CLA Fat x 
CLA 
                                                          g of FAME2 per day 
4:0 56.5 33.9 52.3 37.0 8.84 0.94 0.03 0.60 
6:0 33.7 14.5 31.4 14.8 3.95 0.71 <0.01 0.63 
8:0 20.7 8.8 19.6 8.9 2.72 0.77 <0.01 0.75 
10:0 48.2 20.3 47.6 20.1 7.14 0.93 <0.01 0.96 
12:0 57.6 26.3 62.2 28.0 8.99 0.56 <0.01 0.79 
13:0 3.5 1.4 4.7 1.5 0.73 0.29 <0.01 0.33 
14:0 178.8 102.9 200.7 116.0 21.44 0.13 <0.01 0.67 
14:1(c9) 15.8 10.0 21.5 12.7 2.22 <0.01 <0.01 0.17 
15:0 17.6 8.7 23.5 9.1 3.99 0.30 <0.01 0.35 
16:0 489.4 261.0 512.1 291.0 57.00 0.39 <0.01 0.90 
16:1 (c9) 24.2 14.6 30.0 17.6 3.94 <0.01 <0.01 0.21 
16:1 (c11) 0.6 0.7 1.0 0.9 0.14 <0.01 0.40 0.13 
17:0 7.6 4.5 8.8 4.8 1.19 0.29 <0.01 0.49 
18:0 123.3 85.9 110.8 94.83 15.41 0.87 0.06 0.36 
18:1 384.5 246.9 365.8 255.7 32.39 0.75 <0.01 0.39 
18:2 61.0 48.0 61.4 49.2 5.99 0.81 <0.01 0.89 
18:3 (c9,c12,c15) 3.8 2.4 4.1 2.7 0.31 0.14 <0.01 0.98 
20:0 2.2 1.4 1.2 1.5 0.25 0.81 0.02 0.38 
20:1 (c-9) 1.3 0.8 1.4 0.9 0.14 0.33 <0.01 0.76 
22:0 0.4 0.2 0.3 0.2 0.06 0.60 0.03 0.70 
22:4 0.7 0.3 0.7 0.3 0.12 0.75 <0.01 0.61 
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22:5 0.9 0.4 0.9 0.4 0.13 0.74 <0.01 0.86 
DNFA3 685.7 343.8 710.3 395.9 82.54 0.43 <0.01 0.77 
MUFA4 437.1 280.3 433.1 295.7 37.85 0.72 <0.01 0.54 
PUFA5 68.5 52.9 69.8 54.7 6.75 0.67 <0.01 0.94 
SFA6 1066.9 585.4 1105.0 646.5 127.60 0.51 <0.01 0.88 
1 Probability that the FAT, CLA or interaction effects were not different from zero 
2 Fatty acid methyl esters 
3 Denovo synthesized fatty acids 
4 Monounsaturated fatty acids 
5 Polyunsaturated fatty acids 
























Table 4.7. Least squares means for fatty acid composition of C18:1 and C18:2 isomers in milk fat from cows abomasally 
infused with long-chain FA (LCFA), LCFA with conjugated linoleic acid (LC-CLA), butterfat (BF) and BF with CLA (BF-
CLA) 
 Treatments  P-values1 
Fatty acid LCFA LC-CLA BF BF-CLA SEM Fat CLA Fat x 
CLA 
                                                            g/100 g of FAME2 
18:1         
trans-5/7 0.13 0.20 0.13 0.22 0.02 0.22 <0.01 0.15 
trans-8/9 0.28 0.37 0.36 0.40 0.04 0.03 0.02 0.20 
trans-10 0.37 1.01 0.83 1.08 0.43 0.37 0.17 0.49 
trans-11 0.75 0.92 0.65 0.91 0.11 0.54 0.04 0.61 
trans-12 0.35 0.30 0.34 0.36 0.07 0.66 0.76 0.57 
trans-13/14 0.40 0.56 0.55 0.65 0.05 <0.01 <0.01 0.11 
trans-16 0.19 0.22 0.21 0.26 0.01 <0.01 <0.01 0.32 
Total trans 2.44 3.57 3.08 3.82 0.53 0.16 0.01 0.49 
cis-9 20.94 22.35 18.23 20.35 1.79 0.05 0.10 0.70 
cis-11 0.63 0.71 0.63 0.69 0.07 0.80 0.15 0.70 
cis-12 0.22 0.21 0.25 0.27 0.03 0.11 0.82 0.62 
cis-13 0.04 0.05 0.05 0.07 0.01 0.02 0.01 0.59 
cis-14 0.04 0.03 0.05 0.04 0.00 <0.01 0.04 0.50 
cis-15 0.05 0.07 0.07 0.08 0.01 0.06 0.10 0.30 
cis-16 0.01 0.01 0.01 0.02 0.00 0.11 0.39 0.43 
Total cis 21.92 23.44 19.30 21.49 1.79 0.05 0.09 0.72 
18:2          
trans-11, trans-15 0.02 0.02 0.02 0.02 0.00 0.04 0.69 0.87 
trans 9, trans-12 0.09 0.07 0.10 0.09 0.01 <0.01 0.03 0.49 
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cis-9, trans-13 0.09 0.10 0.15 0.13 0.01 <0.01 0.22 0.04 
trans-11, cis-15 0.04 0.05 0.05 0.05 0.00 0.99 0.44 0.75 
cis-9, cis-12 3.10 3.66 2.85 3.23 0.30 0.26 0.14 0.74 
cis-9, cis-15 0.02 0.04 0.03 0.03 0.00 0.86 0.37 0.18 
CLA         
cis-9, trans-11 0.39 0.87 0.44 0.83 0.09 0.99 <0.01 0.60 
trans-10, cis-12 0.01 0.27 0.01 0.25 0.04 0.77 <0.01 0.71 
trans-7, cis-9 0.04 0.04 0.05 0.04 0.00 0.08 0.60 0.22 
trans-8, cis-10 0.03 0.04 0.03 0.01 0.00 0.13 0.99 0.16 
trans-9, cis-11 0.01 0.03 0.01 0.02 0.00 0.83 <0.01 0.06 
trans-11,trans-13 0.01 0.03 0.01 0.02 0.00 0.26 0.01 0.25 
Total CLA 0.50 1.33 0.56 1.21 0.12 0.81 <0.01 0.47 
1 Probability that the FAT, CLA or interaction effects were not different from zero 


















Table 4.8. Least squares means for fatty acid yield of C18:1 and C18:2 isomers in milk fat from cows abomasally infused with 
long-chain FA (LCFA), LCFA with conjugated linoleic acid (LC-CLA), butterfat (BF) and BF with CLA (BF-CLA) 
 Treatments  P-values1 
Fatty acid LCFA LC-CLA BF BF-CLA SEM Fat CLA Fat x 
CLA 
                                                          g of FAME2 per day 
18:1         
trans-5/7 2.08 1.90 2.12 2.38 0.33 0.07 0.72 0.11 
trans-8/9 4.50 3.59 5.99 4.16 0.87 0.02 <0.01 0.22 
trans-10 5.67 10.69 14.14 13.25 5.83 0.13 0.53 0.38 
trans-11 11.64 8.81 10.69 10.05 1.63 0.88 0.13 0.30 
trans-12 5.61 2.93 5.61 3.81 1.17 0.64 0.06 0.65 
trans-13/14 6.48 5.42 9.13 6.88 1.38 0.01 0.03 0.34 
trans-16 3.01 2.08 3.49 2.68 0.41 0.07 0.01 0.81 
Total trans 39.00 35.43 51.18 41.51 9.83 0.10 0.21 0.54 
cis-9 329.54 201.04 296.56 202.85 24.14 0.23 <0.01 0.19 
cis-11 10.10 6.70 10.65 6.53 1.58 0.79 <0.01 0.61 
cis-12 3.52 1.99 4.12 2.69 0.43 0.04 <0.01 0.86 
cis-13 0.59 0.51 0.86 0.75 0.16 0.01 0.23 0.80 
cis-14 0.58 0.32 0.75 0.40 0.11 <0.01 <0.01 0.14 
cis-15 0.76 0.69 1.18 0.85 0.24 0.03 0.11 0.25 
cis-16 0.18 0.11 0.24 0.18 0.05 0.20 0.18 0.86 
Total cis 345.26 211.37 314.36 213.99 26.03 0.28 <0.01 0.21 
18:2          
trans-11, trans-15 0.31 0.18 0.39 0.23 0.06 0.08 <0.01 0.63 
trans 9, trans-12 1.40 0.69 1.74 0.97 0.25 0.07 <0.01 0.84 
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cis-9, trans-13 1.52 0.99 2.5 1.33 0.32 <0.01 <0.01 <0.01 
trans-11, cis-15 0.69 0.48 0.75 0.52 0.09 0.44 0.02 0.89 
cis-9, cis-12 49.02 33.32 46.47 33.19 4.36 0.55 <0.01 0.59 
cis-9, cis-15 0.37 0.34 0.46 0.30 0.08 0.66 0.08 0.18 
CLA         
cis-9, trans-11 6.12 7.94 7.13 9.04 0.94 0.22 0.06 0.95 
trans-10, cis-12 0.11 2.41 0.17 2.61 0.30 0.61 <0.01 0.77 
trans-7, cis-9 0.60 0.41 0.86 0.47 0.13 0.03 <0.01 0.09 
trans-8, cis-10 0.46 0.36 0.45 0.19 0.11 0.32 0.09 0.38 
trans-9, cis-11 0.16 0.26 0.24 0.25 0.06 0.24 0.11 0.15 
trans-11,trans-13 0.19 0.25 0.26 0.22 0.04 0.54 0.69 0.16 
Total CLA 7.74 12.06 9.07 12.95 1.25 0.32 <0.01 0.83 
1 Probability that the FAT, CLA or interaction effects were not different from zero 
















Table 4.9. Least squares means of desaturase indices in milk from cows abomasally infused with long-chain FA (LCFA), 
LCFA with conjugated linoleic acid (LC-CLA), butterfat (BF) and BF with CLA (BF-CLA) 
 Treatments  P-value1 
SCD1 index2 LCFA LC-CLA BF BF-CLA SEM Fat CLA Fat x 
CLA 
cis-9 14:1 0.083 0.093 0.098 0.099 0.012 0.02 0.13 0.22 
cis-9 16:1 0.047 0.053 0.055 0.057 0.005 <0.01 0.04 0.19 
cis-9 18:1 0.730 0.703 0.728 0.694 0.025 0.68 0.05 0.81 
Overall index3 0.323 0.342 0.299 0.320 0.021 0.08 0.120 0.94 
1Probability that the FAT, CLA or interaction effects were not different from zero 
2Specific ratios for stearoyl-coenzyme A desaturase-1 (SCD1) activity:cis-9 14:1 = (cis-9 14:1)/(cis-9 14:1 + 14:0); cis-9 16:1 
= (cis-9 16:1)/(cis-9 16:1 + 16:0); cis-9 18:1 = (cis-9 18:1)/(cis-9 18:1 + 18:0) 
3Overall SCD1 index was calculated as follows: ([cis-9 14:1] + [cis-9 16:1] + [cis-9 18:1])/ ([cis-9 14:1 + 14:0] + [cis-9 16:1 

























































































Figure 4.2. Relative mRNA abundance of acetyl-CoA carboxylase (ACC) and fatty acid 
synthase (FASN) in response to abomasal infusion of different fat supplements (Bars 
represent the least squares means ± SEM of the respective gene); n-3 or 4 († P < 0.10;* P 
< 0.05;** P < 0.01;*** P < 0.001); LCFA( long-chain fatty acid), LC-CLA (LCFA with 









Figure 4.3. Relative mRNA abundance of acylglycerol-3-phosphate acyl transferase 
(AGPAT) and diacylglycerol acyl transferase (DGAT) in response to abomasal infusion 
of various fat supplements (Bars represent the least squares means ± SEM of the 
respective gene); n-3 or 4 († P < 0.10;* P < 0.05;** P < 0.01;*** P < 0.001); LCFA( 
long-chain fatty acid), LC-CLA (LCFA with conjugated linoleic acid), BF(Butterfat), 










































































































Figure 4.4. Relative mRNA abundance of lipoprotein lipase (LPL) and stearoyl-CoA 
desaturase (SCD) in response to abomasal infusion of various fat supplements (Bars 
represent the least squares means ± SEM of the respective gene); n-3 or 4 († P < 0.10;* P 
< 0.05;** P < 0.01;*** P < 0.001); LCFA( long-chain fatty acid), LC-CLA (LCFA with 



















































































Figure 4.5. Relative mRNA abundance of sterol regulatory element binding protein 
(SREBP) and peroxisome proliferator activated receptor (PPAR-γ) in response to 
abomasal infusion of various fat supplements (Bars represent the least squares means ±
SEM of the respective gene); n-3 or 4 († P < 0.10;* P < 0.05;** P < 0.01;*** P < 0.001); 
LCFA( long-chain fatty acid), LC-CLA (LCFA with conjugated linoleic acid), BF 




      
 
 
Figure 4.6. Relative mRNA abundance of SREBP cleavage activating protein (SCAP) 
and insulin induced gene 1 protein (INSIG-1) in response to abomasal infusion of various 
fat supplements (Bars represent the least squares means ± SEM of the respectiv  gene); 
n-3 or 4(† P < 0.10;* P < 0.05;** P < 0.01;*** P < 0.001); LCFA( long-chain fatty acid), 
LC-CLA (LCFA with conjugated linoleic acid), BF (Butterfat), BF-CLA (BF with CLA) 
 
 





































































































mammary tissue in response to abomasal infusion of different fat supplements
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Figure 4.8. Immunoblots for
tissue in response to abomasal infusion of different fat supplements
least squares means ± SEM of the FASN
0.10;* P < 0.05;** P < 0.01;*** 
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Chapter 5: EXPERIMENT 3 
 
Rosiglitazone corrects conjugated linoleic acid induced hepatic steatosis but not 
milk fat depression in lactating mice1 
 









1D. Vyas, B. B. Teter, and R. A. Erdman.  2011. The effects of PPAR-γ agonist and 
conjugated linoleic acid on mammary and hepatic lipid metabolism in lactating mice.  J. 




Previous studies have demonstrated the antagonizing effects of PPAR-γ agonists 
on conjugated linoleic acid (CLA)-induced hepatic steatosis and adipose tissue 
lipodystrophy in mice. We hypothesized that the PPAR-γ agonist, Rosiglitazone (ROSI), 
might also antagonize the CLA-induced reduction in milk fat synthesis in lactating mice.  
Our objective was to investigate the combination of ROSI and CLA on mammary and 
hepatic lipogenesis in lactating C57Bl/6J mice. Twenty-four lactating mice were 
randomly assigned to one of four treatments applied from Day 6 to 10 postpartum.  
Treatments included: 1) Control diet; 2) Control plus 1.5 % dietary CLA (CLA); 3) 
Control plus intra-peritoneal (IP) ROSI injections (10 mg/kg BW) (ROSI); and 4) CLA 
plus ROSI (CLA-ROSI). Dam food intake was significantly reduced with CLA while not 
with ROSI. Milk fat concentration was depressed significantly (42%) by CLA but no 
effects were observed with ROSI or ROSI x CLA interaction. The milk fat responses 
from CLA were reflected in mammary lipogenic gene and protein expression. While
CLA significantly reduced mammary lipogenesis including denovo FA synthesis, uptake, 
and desaturation, and TG synthesis, no effects were observed with ROSI. Liver weight 
(g/100g body weight) was significantly increased by CLA due to an increase in lipid 
accumulation. However, ROSI rescued CLA-induced hepatic steatosis. Increased hepatic 
lipid accumulation with CLA triggered a compensatory reduction in mRNA abundance of 
hepatic lipogenic enzymes including ACC and SCD-1. However, the combination of 
ROSI and CLA reduced FASN and tended to reduce ACC and LPL mRNA expression. 
Pup weight gain was significantly reduced with CLA and to a lesser extent by ROSI. 
Overall, ROSI corrected the apparent steatosis effect of CLA but was not able to rescue 
135 
 
CLA-induced milk fat depression. The lack of an effect on mammary lipogenesis with 
ROSI could be explained by its insulin-sensitizing properties as suggested previously, 
that might have increased glucose utilization in peripheral tissues and reducing glucose 





The mammary gland is the most active lipid-synthesizing organ during lactation 
in mice (Rudolph et al., 2007) as it secretes ~ 30 g of milk lipids over the course of the 
20-d lactation period which is equivalent to the dam’s entire body weight (Schwertfeger 
et al., 2003). Milk lipid synthesis involves formation of fatty acids (FA) either denovo in 
the mammary gland or absorption of preformed FA from blood originating in the diet or 
mobilized from adipose tissue (Smith, 1980). Short-and medium-chain FA (SMCFA) 
including C8, C10, C12, C14 and half of C16 are synthesized denovo, while the rest of 
the long-chain FA (LCFA; > 16:0) are absorbed preformed from the blood triglycerides 
(TG). Several mammary lipogenic enzymes are involved in formation of milk fat. 
Mammary acetyl-CoA carboxylase (ACC) and fatty acid synthase (FASN) enzymes are 
involved in the pathway of denovo FA synthesis, while lipoprotein lipase (LPL) is 
involved in uptake of FA from triglyTG. Absorbed and denovo-synthesized FA (DNFA) 
are further esterified to glycerol sequentially via glycerol-3-phosphate acyl transferase 
(GPAT), acylglycerol-3-phosphate acyl transferase (AGPAT), and diacylglycerol acyl 
transferase (DGAT). Saturated LCFA (> C14) could be desaturated by the stearoyl-CoA 
desaturase (SCD) before being incorporated into TG (Bernard et al., 2008).  
Milk fat synthesis is highly responsive to nutritional manipulation in ruminants 
(Sutton, 1989). Certain dietary alterations like a high-fat diet or the specific conjugated 
linoleic acid (CLA) isomer, trans-10, cis-12 CLA, reduce FA synthesis, causing low milk 
fat syndrome commonly termed as milk fat depression (MFD) in dairy cows. The CLA-
induced MFD is characterized by marked reduction of mRNA abundance of enzymes 
involved in mammary lipogenesis (Piperova et al., 2000; Peterson et al., 2003) including 
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major transcription factors such as sterol regulatory element binding protein (SREBP-1) 
(Harvatine and Bauman, 2006) in both dairy cows (Baumgard et al., 2002) and lactating 
mice (Lin et al., 2004). The CLA-induced MFD alters the milk FA composition by 
reducing the proportions of SMCFA to a greater extent than LCFA (Loor and Herbein, 
1998), suggesting decreased denovo FA synthesis. Trans-10, cis-12 CLA has also been 
shown to induce insulin resistance associated with macrophage infiltration and adipose 
tissue lipolysis (Poirier et al., 2005). Trans-10, cis-12 CLA-induced insulin resistance 
causes hyperinsulinemia, further triggering hepatic lipid accumulation, leading to hepatic 
steatosis (Clement et al., 2002; Degrace et al., 2003; Rasooly et al., 2007; Cooper et al., 
2008). The intensity of lipid accumulation depends upon the level and duration of 
feeding, the extent of adipose tissue lipolysis, and the physiological status of the animal 
(Clement et al., 2002; Vyas et al., 2012).  
Peroxisome proliferator activated receptor- γ (PPAR-γ) is an important member 
of the nuclear receptor super family of transcription factors that can be activated by 
lipophilic ligands. It regulates adipocyte differentiation and has been implicated as a key 
protein for thermogenesis and adipose tissue lipid metabolism (Jain et al., 1998). 
Rosiglitazone (ROSI), a PPAR-γ agonist, is commonly used as an insulin sensitizing 
agent for the treatment of Type-2 diabetes mellitus (Moller, 2001). Liu et al. (2007) 
observed antagonistic effects of ROSI on trans-10, cis-12 CLA-induced lipodystrophic 
disorders and hepatic lipid accumulation.  
While the role of PPAR-γ has been extensively studied on adipose and hepatic 
lipid metabolism, its role in the mammary gland is still uncertain (Wan et al., 2007). 
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Recently, a pivotal role of PPAR-γ was observed in maintaining milk quality and 
protecting newborns by reducing the production of inflammatory lipids in lactating 
mammary gland (Wan et al., 2007). Bionaz and Loor (2008) suggested that PPAR- γ 
could be the main transcription factor controlling milk fat synthesis by serving as a 
regulator for SREBP activity. Kadegowda et al. (2009) also showed marked upregulation 
of mammary lipogenic gene expression with ROSI, cultured in bovine mammary 
epithelial cells.  
Because ROSI antagonizes trans-10, cis-12 CLA-induced adipose tissue 
lipodystrophy and hepatic steatosis (Liu et al., 2007) and has been shown to upregulate 
mammary lipogenesis in cell culture, we hypothesized that providing ROSI to lactating 
females will also antagonize trans-10, cis-12 CLA-induced milk fat depression by 
increasing expression of mammary lipogenic enzymes. The main objective of he present 
study was to study the combination of ROSI and CLA on mammary and hepatic 
lipogenesis in lactating mice.  
MATERIALS AND METHODS 
Animals, Diets, and Treatments 
All animal procedures were performed in accordance with the Institutional 
Animal Care and Use Committee (IACUC) of the University of Maryland. Female 
C57Bl/6J mice (Charles River, Wilmington, MA) were bred to obtain pregnant dams. 
Day1 of the lactation was the day on which pups were born. Litters were standardized to 
six pups for all treatments to maintain uniform milk synthesis among dams.  
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Dams and their pups were housed in shoebox cages and provided with ad-libitum 
food and water. Pregnant mice were fed a commercial rodent diet (5001 Rodent Lab Diet 
®, Purina, Richmond, IN) consisting of 23% CP, 4.5% fat, and 6.0% fiber until 2 d 
prepartum. From d-2 prepartum until d-6 postpartum, dams were fed a control diet. 
Twenty-four lactating mice were randomly assigned to one of four treatments (n = 6 per 
treatment) applied from d-6 to d-10 postpartum.  Treatments included: 1) Control diet; 2) 
Control plus 1.5 % dietary CLA (CLA); 3) Control plus intra-peritoneal (IP) ROSI 
injections (10 mg/kg BW) (ROSI); and 4) CLA plus ROSI (ROSI-CLA).  Mice on the 
Control and CLA diets received IP injections of phosphate buffered saline (PBS). Daily 
food intake was recorded during the experimental period. On d-6 and d-10 postpartum, 
milk samples were collected by suction and milk fat percentages measured a previously 
described (Teter et al., 1990). Milk samples were stored at -20°C for FA analyses. Body 
weights of dams and pups were recorded before milking. On d-10 postpartum, the 
animals were sacrificed using carbon dioxide and individual liver and mammary tissues 
were collected from dams and livers were collected and pooled from pups within litters 
from each treatment. Livers were fast-frozen in liquid N2, and stored at -80°C until RNA, 
protein, and lipid extraction. 
Lipid Extraction and FA Analysis  
 The FA composition was analyzed from milk samples collected on d-6 and d-10 
postpartum and dam and pup liver samples collected on d-10 postpartum. The FA methyl 
esters (FAME) were prepared by mild transesterification with 1.4 mol/L of H2SO4
 in 
methanol (Christie, 1982). Separations were achieved using an Agilent 6890N gas 
chromatograph (Agilent Technologies, Wilmington, DE) equipped with a flame 
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ionization detector. Hydrogen was used as carrier gas at 1.6 mL/min with the linear 
velocity of 26.1 cm/s.  Air flow was maintained at 400 mL/min. Nitrogen was used as 
make up gas with flow rate of 28.4 mL/min.  The oven was maintained at 170oC for 50 
min followed by the ramp of 6oC per min to 185oC for 50 min with a total run time of 
102.5 min. The injection port was maintained at 250oC, and the detector at 250oC. The 
split ratio was set to 1:100 and the typical injection volume was 1 uL. Individual FA  
were  identified using GLC-60 and GLC-463 standard mixture (Nu-Chek Prep Inc., 
Elysian, MN).    
RNA Isolation and Quantitative Real-Time Reverse-Transcription PCR 
Frozen biopsy tissues were weighed (~30 mg) and immediately subjected to RNA 
extraction using Qiagen RNeasy mini kit with on-column DNAse digestion (Qiagen, 
Valencia, CA). The RNA concentration and quality was measured using a NanoDrop 
ND-1000 spectrophotometer (Wilmington, DE). The purity of RNA (A260/ 280) for all 
samples was above 1.9.  The RNA integrity was assessed by electrophoretic analysis of 
28S and 18S rRNA subunits using agarose gel electrophoresis.   
A portion of the extracted RNA was diluted to 1µg/µL using DNase-RNase free 
water prior to reverse transcription. The cDNA was synthesized from 1µg RNA using the 
iScript cDNA Synthesis Kit (Bio-Rad Laboratories Inc., Hercules, CA) as per the 
manufacturer’s instructions. A negative control to check for genomic DNA 
contamination was prepared by pooling RNA from each sample, and using 1 µg in a 
reaction without reverse transcriptase. All first-strand cDNA reactions were diluted 5-
fold prior to use in PCR.  
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The primer sequences utilized in these experiments are detailed in Table 5.3. The 
samples were run in duplicates and mRNA levels were quantified using the MyiQ Single-
Color Real-Time PCR Detection System (Bio-Rad) and the 2X Quantitect SYBR Green 
PCR Master Mix (Bio-Rad). Cycles were performed as follows: denaturation t 95oC for 
3 min to activate the polymerase, followed by 40 cycles of 95oC for 15 s, 60oC for 30 s, 
and 72oC for 30 s. The presence of a single PCR product and the absence of primer-
dimers were verified by the melt curve analysis using incremental temperatures to 95°C 
for 15 s plus 65°C for 15 s. Data were normalized to the housekeeping gene β-actin 
(ACTB) and the specificity of PCR product was verified by separating on 1% agarose el. 
The stability of ACTB expression was validated by calculating standard deviation (SD), 
coefficient of variation (CV) and maximum fold change (MFC) (de Jonge et al., 2007). 
The expression of ACTB in liver and mammary tissues had SD of 0.79 and 0.52, CV of 
3.96 and 2.71 and MFC of 1.19 and 1.10 respectively. The data were transformed using 
the equation 2-∆∆Ct (Livak and Schmittgen, 2001), where Ct represents the fractional cycle 
number when the amount of amplified product reaches a threshold for fluorescence. The 
normalized data were transformed to obtain a perfect mean of 1.0 for controls, leavingthe 
proportional difference between the biological replicates. The same proportional change 
was calculated in all the treatments to obtain a fold change relative to controls. 
Protein Isolation and Western Blotting 
 Protein isolation and western blotting procedures were adapted from (Rudolph et 
al., 2010). Briefly, mammary lysis buffer [50 mM Tris (pH 7.4), 150 mM NaCl, 2.0 mM 
EDTA, 50 mM NaF, 5.0 mM sodium vanadate, 1% Triton X-100, 1% deoxycholate, and 
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0.1% SDS] to which 0.57 mM phenylmethylsulfonyl fluoride (PMSF), 20 µL/mL EDTA-
free protease inhibitor cocktail (Roche Applied Science, Indianapolis, IN), and 1.0 mM 
DTT were added to extract proteins from the mammary samples. Samples were 
homogenized using a Brinkman homogenizer, and lysate was centrifuged at 13,000 g for 
20 min at 4°C. Protein concentrations in the supernatant were determined using 
bicinchoninic acid (Pierce, Rockford, IL). Proteins were resolved using 8% SDS-
polyacrylamide gels (Laemmli, 1970). Resolved proteins were transferred to 
nitrocellulose membrane (Biorad laboratories, Hercules, CA).  Antibodies directed 
against acetyl-CoA carboxylase-1 (Polyclonal antibodies raised in rabbit; Catalogue # 
3662S) and fatty acid synthase (Polyclonal antibodies raised in rabbit; Catalogue # 
3180S) and secondary antibodies (Anti-rabbit IgG, HRP linked antibody; Catalogue # 
7074S) were obtained from Cell Signaling Technology, Inc. (www.cellsignal.com, 
Danvers, MA). 
Statistical Analyses 
Data were analyzed using the GLM procedure in the Statistical Analysis Software 
(Version 9.2, SAS Institute, Cary, NC). Data from day 6 postpartum were used as a 
covariate for the analyses of milk fat percentage, milk FA composition, and dam and pup 
body weight. The statistical model included fixed effect of d 6 values (where appropriate) 





 Ingredient and FA composition (g/100 g FAME) of the control and CLA diets are 
presented in Tables 5.1 and 5.2 respectively. The diet was modified from AIN-93 
specifications as mentioned earlier (Teter et al., 1990). The major difference in the FA 
composition of Control and CLA diets was the presence of CLA isomers (mainly cis-9, 
trans-11 and trans-10, cis-12 CLA isomers). Previous studies have shown that cis-9, 
trans-11 CLA isomer had no significant effect on milk fat synthesis and liver and carcass 
FA composition in lactating mice (Loor et al., 2003); hence the effects of CLA 
supplementation on mammary and hepatic lipid metabolism were attributed to the 
presence of trans-10, cis-12 CLA isomer.  
Food Intake, Body and Organ Weights, and Pup Growth Rate 
 Dam daily food intake, body and liver weights and pup growth rates are presented 
in Table 5.4. No effects were observed on the average dam body weight at d-10 
postpartum. However, CLA reduced (P < 0.05) feed intake by 17%. Liver weights were 
increased (P < 0.05) with CLA and the response was more pronounced with control 
treatment (32%) as compared to CLA-ROSI combination (6%). Similar responses wer  
observed when liver weight was presented as % of body weight (BW). However, ROSI 
reduced liver weight (as % of BW) (P < 0.05) by 10% and 13% when given with control 
and CLA treatments respectively. The ROSI x CLA interaction tended to rescue CLA-
induced increase in liver weight (P < 0.10). Liver fat content (measured as FAME per g 
tissue) was increased (P < 0.01) with CLA while no effects were observed with ROSI. 
However, ROSI tended to reduce (P < 0.10) total liver lipids (measured as total FAME). 
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D-10 pup body weight and growth rate were reduced in both CLA (P < 0.001) and ROSI 
(P < 0.05) treatments.  
Milk Fat Content and FA Composition 
 Milk fat content was reduced by 42% with CLA (P < 0.001) but not affected by 
ROSI (Table 5.4). Dietary CLA increased the proportions of trans-10, cis-12 CLA and 
cis-9, trans-11 CLA (P < 0.001 and P < 0.01 respectively) in total milk FA (Table 5.5). 
CLA-induced depression in milk fat concentration was accompanied by reduction in otal 
denovo synthesized FA (DNFA) content (P < 0.001). No effects were observed on short-
chain FA (SCFA, 8:0 and 10:0) while CLA reduced medium-chain FA (MCFA, C12 and 
C14) content (P < 0.05; P < 0.001, respectively). ROSI reduced (P < 0.05) C14 while no 
effects were observed on other SCFA and MCFA. The CLA-induced decrease in MCFA 
led to proportional increase in C18:0 (P < 0.01) and C18:1c9 (P < 0.01). There was an 
ROSI x CLA interaction where ROSI increased (P < 0.05) 18:1c9 with the CLA 
treatment but not with the control. The increase in C18 FA with CLA was accompanied 
with increased total monounsaturated FA (MUFA; P < 0.05) and polyunsaturated FA 
(PUFA; P < 0.05) followed by concomitant reduction in saturated FA (SFA) content (P < 
0.05). The ROSI x CLA interaction was observed for MUFA (P < 0.05) and DNFA (P < 
0.10) where the ROSI-CLA treatment resulted in increased MUFA and decreased DNFA 
with other treatments.  
Hepatic FA Composition 
 The hepatic FA profile (g/100 g of FAME) in dams is shown in Table 5.6. 
Conjugated linoleic acid increased the proportions of its constituent isomers, cis-9, trans-
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11 and trans-10, cis-12 CLA. The CLA diet increased (P < 0.01) the proportion of C16:0 
and C16:1 while no effects were observed on MCFA (C12 and C14). Similarly, C16:0 
content was increased (P < 0.01) and C16:1 content tended to increase (P < 0.10) with 
ROSI treatment.  Trans-10, cis-12 CLA-induced increase in C16:0 led to proportionate 
reduction in the content of C18:0. No CLA effects were observed on C18:1 FA. 
Rosiglitazone tended to increase (P < 0.10) C18:1 content while no effects were observed 
on C18:0. Polyunsaturated FA content including C20:3, C20:4 and C22:6 were reduced 
with CLA. 
 The hepatic FA profiles for pups are presented in Table 5.7. ROSI had no effect 
on pup hepatic FA composition. However, CLA effects were pronounced on MCFA. 
Both C12 and C14 were reduced with CLA (P < 0.01; P < 0.05 respectively). While CLA 
had no effect on C16:0, the content of C16:1 was reduced (P < 0.05).  Trans-10, cis-12 
CLA isomer was transferred from dam milk to pup liver as its content was increased (P < 
0.05) with CLA. The concentration of cis-9, trans-11 CLA was similar across all 
treatments.  
Mammary Lipogenic Gene Expression  
 Mammary lipogenic gene expression data in is presented in Figures 5.1, 5.2, and 
5.3. The mRNA abundance of mammary lipogenic genes coincide with milk fat 
responses observed with CLA as the enzymes involved in denovo FA synthesis were 
reduced. While CLA effects were significant for FASN (P = 0.002), the ACC mRNA 
abundance only tended (P = 0.09) to be reduced with CLA.  The mRNA expression of 
enzymes involved in FA uptake (LPL), desaturation (SCD-1), and TG synthesis (DGAT) 
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were reduced with CLA (P = 0.06; P < 0.001; P < 0.01 respectively). The mRNA 
expression of the transcription factors SREBP-1c (P < 0.001) and PPAR-γ (P = 0.002) 
and transcription co-activators INSIG-1 (P < 0.001), SCAP (P < 0.001) and RXR (P < 
0.001) were also reduced with CLA. No ROSI effects were observed on mRNA 
expression of mammary lipogenic enzymes, SREBP-1c and SREBP-1c co-activators 
SCAP and INSIG-1.  There was a trend for a ROSI by CLA interaction where ROSI 
tended to increase the expression of PPAR-γ (P < 0.10) and RXR (P < 0.10) compared 
with CLA alone.  
 Hepatic Lipogenic Gene Expression  
 Hepatic lipogenic gene expression responses are presented in Figures 5.4, 5.5 and 
5.6. Conjugated linoleic acid treatment reduced hepatic ACC expression (P = 0.01) while 
no effects were observed on FASN. The combination of ROSI along with CLA further 
tended to reduce ACC expression (P = 0.07) while the expression of FASN was reduced 
(P = 0.01) compared with other treatments. Similarly, there was a ROSI by CLA 
interaction where CLA alone increased hepatic LPL expression but not in presence of 
ROSI. The expression of SCD-1 was reduced by CLA (P = 0.02) while ROSI increased 
the DGAT mRNA expression (P = 0.02). Among transcription factors, expression of 
SREBP-1c was reduced (P < 0.05) with CLA while ROSI x CLA interaction tended to 
decrease (P < 0.10) PPAR-γ expression compared to CLA and ROSI alone. Transcription 
activators INSIG-1, SCAP and RXR were not affected by treatments.  
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Mammary and hepatic protein expression 
 The mammary and hepatic protein abundance for ACC and FASN relative to the 
levels of β-tubulin are presented in Figure 5.7 and 5.8, respectively. The protein 
abundance of ACC and FASN in mammary gland was (P < 0.01) reduced with CLA 
while no effects were observed with ROSI. Mammary protein abundance for ACC and 
FASN mirrored gene expression responses shown in Figure 5.1 but not hepatic gene 
expression for the enzymes shown in Figure 5.4.  
DISCUSSION 
 The role of trans-10, cis-12 CLA in suppressing mammary lipogenesis has been 
extensively studied (Bauman et al., 2011). The coordinated downregulation of mammary 
lipogenic genes suggested an important role of transcription factor, SREBP-1c during 
milk fat synthesis (Harvatine and Bauman, 2006). However, recently the role of PPAR-γ, 
a member of nuclear receptor family of transcription factor, was suggested as a potential 
regulator of mammary lipogenesis (Bionaz and Loor, 2008). That assumption was 
supported by recent findings where mammary lipogenesis was upregulated with ROSI, a 
PPAR-γ agonist, in bovine mammary epithelial cells (Kadegowda et al., 2009).   
 Dietary CLA reduced dam food intake but no effects were observed of reduced 
food consumption for body weight. The food intake effects of trans-10, cis-12 CLA were 
comparable to previous reports with lactating mice (Park et al., 1999; Loor et al., 2003). 
The effects of trans-10, cis-12 CLA on dam body weight have been consistent. Body 
weight was reduced by 17% in some (Loor et al., 2003) while no effect was observed in 
others (Kadegowda et al., 2010). The responses on body weight vary depending on level 
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and duration of trans-10, cis-12 CLA feeding, extent of adipose tissue lipolysis, and 
physiological stage of animal (Park et al., 1997; Clement et al., 2002; Larsen et al., 2003; 
Vyas et al., 2012). Dietary trans-10, cis-12 CLA supplement was fed from d-6 to d-10 in 
the present study at dose rate of 0.6% of total diet and the response was comparable to the 
study with a similar dose and feeding duration (Kadegowda et al., 2010). However, dam 
body weight reduced by 35% when trans-10, cis-12 CLA was fed from d 4 to d 15 
postpartum at dose rate of 0.96% of total diet (Loor et al., 2003). In addition to dose and 
duration, CLA reduced milk fat secretion, thereby reducing energy needs of the dam such 
that BW can be maintained in the face of reduced food intake. The growth rate in pups 
from dams fed CLA diet was reduced indirectly perhaps due to reduced energy intake.
However, hepatic FA profile in pups from dams fed CLA diet showed increased trans-10, 
cis-12 CLA from suggesting direct effects of CLA on pup growth rate. The results were 
comparable to previous studies (Loor et al., 2003; Kadegowda et al., 2010). However, 
some studies in lactating rats showed improved pup growth rate with CLA (Poulos et a ., 
2001). The inconsistencies in the growth rate response could be attributed to species-
specific effects of CLA.  
While CLA reduced milk fat content in a manner comparable to previous studies 
(Loor et al., 2003; Kadegowda et al., 2010) there were no effects of ROSI or ROSI x 
CLA interaction on milk fat responses. Reduced milk fat content with CLA diet was 
accompanied by reduced proportions of DNFA including C12 and C14 suggesting 
inhibition of denovo FA synthesis. The mRNA and protein expression of ACC and FASN, 
,critical enzymes catalyzing denovo FA synthesis, were also reduced further reflecting the 
CLA-induced changes observed in milk FA composition. Along with FA synthesis, the 
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mRNA abundance of genes regulating FA uptake (LPL) was also reduced suggesting 
reduced uptake of preformed FA from blood TG.  
The CLA-induced inhibition of FA desaturation was demonstrated by reduced 
mRNA abundance of SCD-1, along with the ratio of 18:1c9/18:0 providing indirect 
evidence of reduced SCD-1 activity. These desaturation effects were comparable to those 
with previous studies in lactating mice (Lin et al., 2004).   
 Trans-10, cis-12 CLA reduced the mRNA expression of DGAT-1, an enzyme 
catalyzing the final and committed step in the process of TG synthesis (Sorensen et al., 
2008). However, no CLA effect was observed on DGAT-1 mRNA expression in MACT 
cells (Sorensen et al., 2008). In the same study the enzyme activity was reduced. The 
difference in both studies could be attributed to different models used for studying milk 
fat synthesis. The animal model used in the present study is more representative of the 
biological system as compared to cell lines used earlier (Sorensen et al., 2008).  
Although the molecular mechanisms regulating milk fat synthesis are not well 
established, the coordinated down-regulation of mammary lipogenesis suggests the 
involvement of transcription regulation (Harvatine and Bauman, 2006). The role of 
SREBP-1 has been suggested as a global regulator of mammary lipid metabolism 
(Rudolph et al., 2007) and is synthesized as precursor protein associated with SCAP and 
anchored to the endoplasmic reticulum with INSIG protein. Upon activation, the SREBP-
1 precursor undergoes a sequential two step cleavage process and the mature protein is
translocated to the nucleus where it binds the target genes on sterol response elements 
(Sakai et al., 1998, Wang et al., 1994). The mRNA expression of SREBP-1c along with 
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SCAP and INSIG-1 were reduced with CLA. The results are comparable to previous 
studies with trans-10, cis-12 CLA in cows (Harvatine and Bauman, 2006; Kadegowda et 
al., 2010) suggesting both transcriptional and post-transcriptional modification of 
SREBP-1c synthesis.  
Gene expression of PPAR-γ was reduced with CLA in mammary gland. As 
expected, ROSI increased PPAR-γ expression and there was as ROSI x CLA interaction 
where the reduction due to CLA was modulated by ROSI. The role of PPAR-γ has been 
extensively studied in relation to adipose and hepatic lipid metabolism but its effect on 
mammary lipid metabolism is not well documented. Present study has provided little 
evidence of its involvement in CLA-induced MFD.  
The lack of ROSI effects on mammary lipogenesis might be attributed to its 
insulin sensitizing properties. Glucose is required for synthesis of free FA in mice 
mammary gland (Anderson et al., 2007). Previous studies using 14C have shown that 40-
70% of fatty acid synthesized is derived from glucose metabolized through pentose 
phosphate pathway (Abraham and Chaikoff, 1959). Rosiglitazone increases the 
peripheral utilization of glucose (Ye et al., 2004) thereby reducing the glucose 
availability as carbon source for DNFA synthesis in mammary gland.  
 The effects of CLA and ROSI on hepatic lipid metabolism in the present study 
were determined by measuring dam liver weight and FA composition along with 
lipogenic gene and protein expression. Dietary CLA increased the liver weight due to
increased lipid accumulation. The response is comparable to previous study using trans-
10, cis-12 CLA in lactating mice (Kadegowda et al., 2010). Increased lipid accumulation 
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can be attributed to various factors including increased FA influx, increased FA synthesis 
and reduced FA oxidation and TG secretion (Jourdan et al., 2009). However mRNA 
expression profile suggests a compensatory response to counteract CLA-induced elevated 
lipid accumulation. The mRNA abundance of ACC along with SCD and SREBP-1c were 
reduced while no effects were observed on FASN, LPL, and DGAT expression with 
dietary CLA. Previous studies with liver specific ACC -1 knockout mice failed to be 
protected against high fat/high carbohydrate diet-induced obesity and fatty liver (Mao et 
al., 2006) due to a compensatory increase in the expression of ACC-2. Similarly, tissue 
specific FASN knockout did not protect against the development of fatty liver but rather 
exacerbated it by reducing FA oxidation (Chakravarthy et al., 2005). While the gene 
expression involved in lipogenesis was reduced in the present study with CLA, the 
increased hepatic lipid accumulation might have resulted from either increased uptake of 
FA, reduced FA oxidation or secretion (Vyas et al., 2012). The responses observed in this 
study contrast with those in previous studies with lactating mice (Lin et al., 2004; 
Kadegowda et al., 2010) where the hepatic lipogenic gene expression remained unaltered 
in response to trans-10, cis-12 CLA. Rosiglitazone rescued trans-10, cis-12 CLA-
induced hepatic steatosis. These results were comparable to earlier study demonstrating 
antagonistic effects of ROSI on trans-10, cis-12 CLA-induced adipose tissue 
lipodystrophy and hepatic steatosis (Liu et al., 2007). The reduced hepatic liid 
accumulation with ROSI x CLA interaction correlates well with the lipogenic gene 
expression. The mRNA expression of FASN was reduced while that of ACC tended to 
reduce with the combination of ROSI and CLA. Findings are comparable to previous 
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study studying combination of ROSI and CLA on hepatic lipid metabolism (Liu et al., 
2007).  
The effects of CLA and ROSI can further be elucidated with the hepatic FA 
profile. The hepatic FA composition during non-alcoholic fatty liver disease (NAFLD) is 
characterized by substantial reductions in long chain polyunsaturated FA (LC-PUFA) 
concentrations; specifically that of arachidonic acid (20:4n-6), eicosapentaenoic cid 
(EPA, 20:5n-3) and docosahexaenoic acid (DHA, 22:6n-3) (Belury and KempaSteczko, 
1997; Sebedio et al., 2001; Chardigny et al., 2003; Kelley et al., 2004; Kelley et al., 2006; 
Kadegowda et al., 2010; Martins et al., 2011). The hepatic FA profile in CLA fed mice in 
the present study was similar to that observed during NAFLD with reduced LC-PUFA 
concentrations.  
It has been shown that normalizing the levels of LC-PUFA can ameliorate hepatic 
steatosis when supplemented along with CLA.  Supplementing arachidonic acid (Oikawa 
et al., 2009) or its precursor γ-linolenic acid (18:3 n-6) (Nakanishi et al., 2004) decreased 
induction of hepatic steatosis. Similarly, supplementing 20:5n-3 and 22:6n-3 prevents 
lipid accumulation when fed with trans-10, cis-12 CLA (Vemuri et al., 2007, Yanagita et 
al., 2005). In the present study the concentrations of LC-PUFA including 18:2n-6, 20:3 
and 22:6 were increased while the concentrations of 20:4 and 20:5 tended to increase 





Trans-10, cis-12 CLA-induced MFD in lactating mice was also associated with 
increased lipid accumulation in liver leading to hepatic steatosis. Administration of ROSI 
had no effect on mammary lipogenesis and failed to rescue CLA-induced MFD. However 
ROSI prevented CLA-induced hepatic steatosis.  
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Table 5.1. Composition of experimental diets fed to lactating mice1 
Ingredients Control CLA 
Sucrose 62.95 62.95 
Soybean oil 7 5.5 
Solka floc2 5 5 
AIN-93 Mineral mix2 3.5 3.5 
AIN-93 Vitamin mix 1 1 
L-Cystine 0.3 0.3 
Choline biTartarate 0.25 0.25 
Casein2 20 20 
Clarinol3 ------ 1.5 
Water Q.S. Q.S. 
1 Modified from AIN-93 specifications 
2 ICN biomedicals 
















Table 5.2.  Fatty acid composition (g/100 g FAME) of lipids added to diets of lactating 
mice 
FA Control1 CLA2 
8:0 0.01 0.01 
10:0 0.04 0.04 
12:0 0.06 0.06 
14:0 0.26 0.24 
15:0 0.04 0.03 
14:1  0.02 0.01 
16:0 10.94 8.06 
16:1  0.11 0.10 
17:0 0.12 0.10 
17:1   0.06 0.05 
18:0 3.92 2.88 
18:1 cis-9 21.39 17.89 
18:1 cis-11 1.41 1.09 
18:2  52.45 41.05 
18:3  7.00 5.04 
20:1 0.21 0.16 
18:2 trans-8,cis-10 0.02 0.33 
18:2 trans-9,cis-11 0.03 0.30 
18:2, cis-9,trans-11 0.08 9.84 
18:2, trans, trans 0.09 0.83 
18:2, trans-10,cis-12 ND3 10.54 
C22:6 0.03 0.03 
1 Soybean oil (7% of diet) 
2 Soybean oil + Clarinol (5.5% and 1.5% of diet respectively) 












Table 5.3.  Primers used for RT-PCR analysis  
Gene Accession #  Primers (5’-3’)1 bp2 Reference 
FASN NM_00798  F ACCTCTCCCAGGTGTGTGAC 106 Kadegowda et al., 2010 
   R TGGATGATGTTGATGATGG   
ACACA NM_13360 F GAAAATCCACAATGCCAAC 106 Kadegowda et al., 2010 
   R GTCCCAGACGTAAGCCTTCA   
SCD-1 NM_00912 F TCCAGTGAGGTGGTGTGAAA 124 Kadegowda et al., 2010 
   R TTATCTCTGGGGTGGGTTTG   
LPL NM_008509 F AGCCCTTGCTAGGAGAAAGC 119 Kadegowda et al., 2010 
  R GGGATGCCGGTAACAAATT   
SREBP-1c NM_011480 F GTGAGCCTGACAAGCAATCA 103 Kadegowda et al., 2010 
  R GGTGCCTACAGAGCAAGAG   
PPAR-G NM_01114 F TGCAGCTCAAGCTGAATCA 94 Kadegowda et al., 2010 
  R ACGTGCTCTGTGACGATCTG   
RXR NM_011305 F TCCTTGGGAGGGTCTTCTCT 107 Kadegowda et al., 2010 
  R GGGCAGGTAGCAACACAGA   
SCAP NM_001144 F TCAGCCAAACATTTGCTCA 106 Kadegowda et al., 2010 
  R CTGCGGTCCCAGATACTGA   
INSIG-1 NM_15352 F TGAGTCGCTGTCTGCTGTTT 105 Kadegowda et al., 2010 
  R TCACAGATTGCAAGCTCCAC   
ACTB NM_007393.3 F AGCCATGTACGTAGCCAT CC 228 This study 
  R CTCTCAGCTGTGGTGGTGAA   
1 Primer direction (F – forward; R – reverse)  
2 Amplicon size in base pair (bp) 
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Table 5.4. Effects of different treatments on dam body weight, food intake, milk fat, liver weight and pup growth rate  
 Treatments  P values 











Dams2         
n 6 6 6 6     
Body weight, g 27.8 27.2 27.3 28.1 0.59 0.576 0.992 0.288 
Intake, g/d 7.02 5.77 7.60 6.36 0.496 0.255 0.021 0.993 
Milk fat, % 2 34.4 21.3 34.2 19.0 1.112 0.255 <0.001 0.301 
Liver wt., g 2.03 2.67 2.16 2.30 0.122 0.350 0.026 0.092 
Liver wt., % of BW 8.31 9.76 7.50 8.53 0.399 0.014 0.006 0.573 
Liver FAME3, mg/g 
tissue 
87.5 160.0 67.0 119.8 23.24 0.215 0.019 0.680 
Total liver FAME, g 0.21 0.43 0.14 0.25 0.632 0.074 0.019 0.375 
Pups (n=6 / litter)         
Day 10 pup weight, g 5.29 4.74 5.04 4.28 0.142 0.012 0.001 0.463 
Pup weight gain, g/d 0.50 0.22 0.39 0.20 0.034 0.073 <0.001 0.196 
1 Values are least squares means ± SEM. 
2 Volume percent (ml/100ml milk) 







Table 5.5. Effects of different treatments on milk fatty acid composition in lactating mice 
 Treatments  P-Value 
Fatty acid CON CLA ROSI ROSI-CLA SEM ROSI CLA ROSI x 
CLA 
                                                        g/100 g of FAME1 
8:0 0.11 0.21 0.16 0.13 0.075 0.741 0.448 0.341 
10:0 2.81 2.71 2.47 2.48 0.947 0.772 0.964 0.951 
12:0 7.21 4.98 5.87 3.87 0.884 0.202 0.044 0.902 
12:1 0.08 0.02 0.10 0.02 0.006 0.028 <0.001 0.121 
14:0 11.4 5.6 10.0 4.3 0.560 0.039 <0.001 0.936 
14:1(c9) 0.24 0.04 0.20 0.07 0.046 0.396 0.019 0.563 
15:0 0.02 0.03 0.02 0.06 0.019 0.220 0.252 0.301 
16:0 30.1 30.8 41.2 26.3 5.72 0.580 0.252 0.210 
16:1 (c9) 2.77 1.79 2.46 2.95 0.310 0.204 0.449 0.043 
17:0 0.40 0.69 0.36 0.80 0.032 0.317 <0.001 0.048 
18:0 1.97 4.69 2.26 3.92 0.610 0.702 0.007 0.406 
18:1(c9) 19.8 21.6 15.8 26.0 1.39 0.877 0.002 0.017 
18:1 (c11) 2.03 1.91 1.63 2.47 0.160 0.637 0.047 0.015 
18:2 (c9c12) 13.5 14.7 11.4 14.9 1.52 0.512 0.161 0.477 
18:2 (c9t11) 1.09 1.96 0.98 2.70 0.352 0.390 0.006 0.253 
18:2 (c11t13) ND2 0.02 ND 0.04 0.01 0.66 <0.001 0.66 
18:2 (t8c10) ND 0.04 ND 0.07 0.027 0.564 0.031 0.564 
18:2 (t9c11) ND 0.04 ND 0.06 0.020 0.615 0.001 0.483 
18:2 (t10c12) ND 1.68 ND 1.48 0.231 0.64 <0.001 0.65 
18:2 (t,t) ND 0.31 ND 0.26 0.052 0.54 0.002 0.48 
18:3 (c6,c9,c12) 0.11 0.29 0.13 0.31 0.026 0.590 <0.001 0.977 
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18:3 (c9,c12,c15) 1.14 1.08 0.90 1.00 0.161 0.341 0.935 0.629 
20:1 (c-9) 0.76 0.59 0.61 0.55 0.051 0.100 0.069 0.320 
20:3 (c8,c11,c14) 0.68 0.25 0.68 0.38 0.091 0.470 0.003 0.522 
20:4 0.49 0.95 0.51 1.01 0.152 0.798 0.020 0.881 
20:5 0.13 0.15 0.14 0.23 0.053 0.412 0.252 0.440 
22:6 0.25 0.42 0.28 0.39 0.071 0.963 0.074 0.684 
Other 2.94 2.48 2.00 3.25 0.11 0.99 0.71 0.51 
DNFA3 36.8 28.9 39.2 24.0 1.76 0.492 <0.001  0.07 
MUFA4 23.9 24.0 19.4 29.7 1.81 0.763 0.021 0.021 
PUFA5 17.5 21.9 15.0 22.8 2.12 0.711 0.021 0.456 
SFA6 53.9 49.6 62.2 41.8 4.59 0.965 0.027 0.118 
<16:0 22.1 13.5 18.8 10.9 2.43 0.262 0.010 0.905 
16:0 30.06 30.80 41.19 26.34 5.72 0.58 0.25 0.21 
>16:0 42.7 51.5 36.0 56.8 3.05 0.823 0.001 0.082 
1 Fatty acid methyl esters 
2 ND, Not detected < 0.005 g/100 g FAME 
3 Denovo synthesized fatty acids 
4 Monounsaturated fatty acids 
5 Polyunsaturated fatty acids 







Table 5.6. Effects of different treatments on hepatic fatty acid composition in lactating mice 
 Treatments  P-Value 
Fatty acid CON CLA ROSI ROSI-
CLA 
SEM ROSI CLA ROSI x 
CLA 
                                                        g/100 g of FAME1 
12:0 0.02 0.03 0.03 0.02 0.007 0.210 0.282 0.111 
14:0 0.82 0.82 0.85 1.19 0.330 0.322 0.294 0.608 
16:0 20.0 26.4 17.1 21.7 1.98 0.021 0.008 0.598 
16:1 (c7) 1.11 1.25 0.80 0.97 0.187 0.074 0.370 0.930 
16:1 (c9) 1.16 2.25 1.12 1.84 0.230 0.083 0.001 0.344 
18:0 14.4 8.9 15.8 10.8 2.40 0.236 0.030 0.904 
18:1(c9) 35.5 42.3 22.0 33.9 6.87 0.058 0.156 0.670 
18:1 (c11) 3.68 4.13 3.47 3.89 0.544 0.523 0.360 0.977 
18:2 (c9c12) 11.0 7.40 14.2 7.90 0.933 0.007 <0.001 0.131 
18:2 (c9t11) 0.66 0.79 0.45 0.85 0.19 0.444 0.162 0.410 
18:2 (t10c12) ND2 0.22 ND 0.24 0.01 0.722 <0.001 0.133 
18:3 (c9,c12,c15) 0.16 0.17 0.33 0.15 0.049 0.041 0.123 0.051 
20:1  1.24 0.83 0.66 0.73 0.240 0.127 0.310 0.260 
20:3 (c8,c11,c14) 0.83 0.29 1.46 0.54 0.047 <0.001 <0.001 0.005 
20:4 5.42 1.63 7.62 3.12 2.17 0.09 0.003 0.152 
20:5 0.02 0.02 0.04 0.05 0.010 0.070 0.012 0.423 
22:0 0.14 0.06 0.08 0.08 0.050 0.731 0.241 0.400 
22:6 2.15 0.59 6.62 1.01 1.306 0.021 0.017 0.103 
1 Fatty acid methyl esters 





Table 5.7. Effects of different treatments on pup liver fatty acid composition 
 Treatments  P-Value 
Fatty acid CON CLA ROSI ROSI-
CLA 
SEM ROSI CLA ROSI*CLA 
                                                        g/100 g of FAME1 
12:0 0.69 0.15 0.62 0.14 0.048 0.503 0.003 0.680 
14:0 2.20 0.74 2.43 0.56 0.300 0.454 0.013 0.580 
16:0 23.6 23.2 24.1 21.0 2.20 0.770 0.469 0.630 
16:1 (c9) 0.75 0.55 1.00 0.38 0.082 0.440 0.013 0.103 
18:0 11.90 17.68 10.02 15.80 2.41 0.220 0.053 0.998 
18:1(c9) 10.41 11.42 13.81 9.20 1.99 0.858 0.360 0.300 
18:1 (c11) 1.79 1.90 1.82 1.78 0.171 0.775 0.953 0.730 
18:2 (c9c12) 16.7 16.0 20.1 13.6 1.26 0.675 0.060 0.129 
18:2 (c9t11) 0.77 1.12 0.76 0.61 0.302 0.272 0.850 0.382 
18:2 (t10c12) ND2 0.35 ND 0.29 0.061 0.230 0.014 0.647 
18:3 (c9,c12,c15) 0.47 0.31 0.55 0.20 0.04 0.687 0.007 0.111 
20:4 11.98 13.12 9.90 12.62 1.352 0.386 0.254 0.636 
20:5 0.28 0.26 0.35 0.24 0.062 0.693 0.352 0.616 
22:0 0.04 0.04 0.04 0.02 0.008 0.512 0.179 0.343 
22:4 0.62 0.45 0.34 0.36 0.280 0.507 0.820 0.711 
22:5 0.86 0.51 0.79 0.48 0.134 0.951 0.052 0.882 
22:6 10.18 8.00 8.65 7.06 2.61 0.692 0.434 0.896 
1 Fatty acid methyl esters 






Figure 5.1. Relative mRNA abundance of mammary lipogenic enzymes ac tyl-CoA 
carboxylase (ACC), fatty acid synthase, lipoprotein lipase (LPL) and stearoyl-CoA 
desaturase (SCD) in response to different treatments. Data are expressed as relative to 
control fed mice (n=6 mice per treatment group; † P < 0.1;* P < 0.05;** P < 0.01;*** P 
< 0.001) 
                   
                                    
                  
       
 
 










































































































Figure 5.2. Relative mRNA abundance of mammary diacylglycerol acyl transferase 
(DGAT), sterol regulatory element binding protein-1 (SREBP-1), peroxisosome 
proliferator activated receptor (PPAR-γ) and insulin induced gene-1 (INSIG-1) in 
response to different treatments. Data are expressed as relative to control fed mice (n=6 
mice per treatment group; † P < 0.1;* P < 0.05;** P < 0.01;*** P < 0.001)                   
                                    
                  














































































































Figure 5.3. Relative mRNA abundance of mammary SREBP cleavage activating protein 
(SCAP) and retinoid X receptor (RXR) in response to different treatments. Data are 
expressed as relative to control fed mice (n=6 mice per treatment group; † P < 0.1;* P < 
0.05;** P < 0.01;*** P < 0.001) 
                                    
                  



































































Figure 5.4. Relative mRNA abundance of hepatic  lipogenic enzymes ac tyl-CoA 
carboxylase (ACC), fatty acid synthase, lipoprotein lipase (LPL) and stearoyl-CoA 
desaturase (SCD) in response to different treatments. Data are expressed as relative to 
control fed mice (n=6 mice per treatment group; † P < 0.1;* P < 0.05;** P < 0.01;*** P 
< 0.001) 
                   
 
                                    
                  












































































































Figure 5.5. Relative mRNA abundance of hepatic d acylglycerol acyl transferase 
(DGAT), sterol regulatory element binding protein-1 (SREBP-1), peroxisosome 
proliferator activated receptor (PPAR-γ) and SREBP cleavage activating protein (SCAP) 
in response to different treatments. Data are expressed as relative to control fed mice 
(n=6 mice per treatment group; † P < 0.1;* P < 0.05;** P < 0.01;*** P < 0.001)   
                                    
                  










































































































Figure 5.6. Relative mRNA abundance of hepatic insulin induced gene-1 (INSIG-1) and 
retinoid X receptor (RXR) in response to different treatments. Data are expressed as 
relative to control fed mice (n=6 mice per treatment group; † P < 0.1;* P < 0.05;** P < 
0.01;*** P < 0.001) 
  
 
                   
                                    
                  



























































Figure 5.7. Relative protein abundance of 
fatty acid synthase (FASN
relative to control fed mice
0.01;*** P < 0.001) 
 
 















































mammary acetyl-CoA carboxylase (
) in response to different treatments. Data are expressed as 
 (n=6 mice per treatment group; † P < 0.1;* P
    

































Figure 5.8. Relative protein abundance of
fatty acid synthase (FASN
relative to control fed mice (n=6 mice per treatment group;
































 hepatic acetyl-CoA carboxylase (
) in response to different treatments. Data are expressed as
 † P < 0.1;* P
    






































































The overall objective of the dissertation was to study the potential limitation of 
denovo synthesized fatty acids (DNFA) during milk fat synthesis. In the first study, the 
availability of SMCFA, added in proportion as synthesized d novo in the mammary 
gland, was increased via dietary supplementation in lactating dairy cows. In a ubsequent 
study, butterfat (BF), used as a source of SMCFA, was abomasally infused during 
conjugated linoleic acid (CLA)-induced milk fat depression (MFD) in lactating dairy 
cows. Finally, Rosiglitazone (ROSI), a peroxisome proliferator activated receptor-γ 
(PPAR- γ) agonist, was used in lactating mice, in an effort to upregulate denovo fatty acid 
(FA) synthesis during CLA-induced MFD.  
 The results from the studies demonstrated small and non-significant changes in 
milk fat output in response to SMCFA. Dietary supplementation of SMCFA had no effect 
on milk fat yield (Figure 6.1). The lack of milk fat response could be attributed to 
reduced milk yield at higher levels of SMCFA supplementation. The inefficient transfer 
efficiency of short chain FA (SCFA) including C8 and C10 possibly due to their 





Figure 6.1. The effects of supplemental short-and medium-chain fatty acids on milk fat 
synthesis (Modified from Baumgard, L. H., 2002) 
In a subsequent study, intestinal availability of SMCFA with BF infusion failed to 
rescue CLA-induced MFD (Figure 6.2). The transfer efficiency of SCFA was very low, 
reflecting the trend observed in first study. In addition, SMCFA had no effects on 
mammary lipogenic gene and protein expression. The results suggest that nutritional 
manipulation with intestinal SMCFA was insufficient to rescue CLA-induced MFD and 
that MFD was not solely due to lack of SMCFA precursors.   
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Figure 6.2. The effects of short-and medium-chain fatty acids during conjugated linoleic 
acid-induced milk fat depression on mammary lipogenesis (Modified from Baumgard L. 
H., 2002) 
Finally, ROSI failed to upregulate mammary lipogenesis and rescue CLA-induced 
MFD in lactating mice (Figure 6.3). On the contrary, CLA-induced MFD was further 
increased in presence of ROSI.  The results suggested indirect effects of ROSI on 
mammary gland possibly via increased insulin sensitivity and reducing glucose 
availability to mammary gland for milk fat synthesis. However, ROSI rescued CLA-
induced hepatic steatosis by reducing hepatic lipid accumulation.  
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Figure 6.3. The effects of Rosiglitazone, a PPAR-γ agonist, during conjugated linoleic 
acid-induced milk fat depression on mammary lipogenesis in lactating mice (Modified 
from Baumgard, L. H., 2002)  
To summarize the overall findings, increased availability of nutrient precursors 
failed to elicit any milk fat responses possibly due to a lack of effect on mammary 
lipogenic gene and protein expression. Our results further support the role of sterol 
regulatory element binding protein-1 (SREBP-1) as major regulator of mammary 
lipogenesis while the role of PPAR- γ could not be ascertained.   
FUTURE DIRECTIONS 
 Despite advances in our understanding of the role of fatty acids (FA) as regulators 
of mammary lipogenesis many issues remain unresolved. Previous studies have largely 
focused on the role of long-chain fatty acids (LCFA) in regulating mammary lipogenesis. 
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However, future research should be focused on studying the role of individual SMCFA in 
regulating milk fat synthesis. Because of the limitation of cell culture techniques, most 
notably the failure to actively secrete milk fat, future studies should either be performed 
in animal models or freshly isolated tissues capable of secreting milk fat to ensure 
relevance to the animal’s physiology.  
 Previous studies have demonstrated positive correlation between fat percentage 
and proportion of SCFA (Palmquist et al, 1993). The transfer efficiency and 
concentration of SCFA in milk fat was not increased in the present studies despite 
increasing availability via diet and abomasal infusion. This suggests that future studies 
should focus on studying the mechanisms regulating the concentration of SCFA in milk 
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